vmal/med-advisor-conversation-4B
1
0
Fork 0
Code Issues Pull Requests Actions Projects Releases Wiki Activity

初始化项目，由ModelHub XC社区提供模型

Browse Source 
Model: vmal/med-advisor-conversation-4B
Source: Original Platform
This commit is contained in:
ModelHub XC
2026-10-22 14:34:18 +08:00
commit 9014162b7a
38 changed files with 153948 additions and 0 deletions
Download Patch File Download Diff File Expand all files Collapse all files

38
.gitattributes vendored Normal file
View File

@@ -0,0 +1,38 @@
*.7z filter=lfs diff=lfs merge=lfs -text
*.arrow filter=lfs diff=lfs merge=lfs -text
*.bin filter=lfs diff=lfs merge=lfs -text
*.bz2 filter=lfs diff=lfs merge=lfs -text
*.ckpt filter=lfs diff=lfs merge=lfs -text
*.ftz filter=lfs diff=lfs merge=lfs -text
*.gz filter=lfs diff=lfs merge=lfs -text
*.h5 filter=lfs diff=lfs merge=lfs -text
*.joblib filter=lfs diff=lfs merge=lfs -text
*.lfs.* filter=lfs diff=lfs merge=lfs -text
*.mlmodel filter=lfs diff=lfs merge=lfs -text
*.model filter=lfs diff=lfs merge=lfs -text
*.msgpack filter=lfs diff=lfs merge=lfs -text
*.npy filter=lfs diff=lfs merge=lfs -text
*.npz filter=lfs diff=lfs merge=lfs -text
*.onnx filter=lfs diff=lfs merge=lfs -text
*.ot filter=lfs diff=lfs merge=lfs -text
*.parquet filter=lfs diff=lfs merge=lfs -text
*.pb filter=lfs diff=lfs merge=lfs -text
*.pickle filter=lfs diff=lfs merge=lfs -text
*.pkl filter=lfs diff=lfs merge=lfs -text
*.pt filter=lfs diff=lfs merge=lfs -text
*.pth filter=lfs diff=lfs merge=lfs -text
*.rar filter=lfs diff=lfs merge=lfs -text
*.safetensors filter=lfs diff=lfs merge=lfs -text
saved_model/**/* filter=lfs diff=lfs merge=lfs -text
*.tar.* filter=lfs diff=lfs merge=lfs -text
*.tar filter=lfs diff=lfs merge=lfs -text
*.tflite filter=lfs diff=lfs merge=lfs -text
*.tgz filter=lfs diff=lfs merge=lfs -text
*.wasm filter=lfs diff=lfs merge=lfs -text
*.xz filter=lfs diff=lfs merge=lfs -text
*.zip filter=lfs diff=lfs merge=lfs -text
*.zst filter=lfs diff=lfs merge=lfs -text
*tfevents* filter=lfs diff=lfs merge=lfs -text
tokenizer.json filter=lfs diff=lfs merge=lfs -text
assets/healthbench.png filter=lfs diff=lfs merge=lfs -text
assets/launch-conversation.png filter=lfs diff=lfs merge=lfs -text

198
README.md Normal file
View File

@@ -0,0 +1,198 @@
---
license: apache-2.0
base_model: Qwen/Qwen3-4B
base_model_relation: finetune
library_name: transformers
pipeline_tag: text-generation
language:
- en
thumbnail: https://huggingface.co/vmal/med-advisor-conversation-4B/resolve/main/assets/launch-scorecard.png
tags:
- medical
- healthcare
- biology
- medical-education
- chat
- conversational
- reasoning
- qwen
- qwen3
- reinforcement-learning
---
# Med Advisor Conversation 4B
**A 4B medical explainer that adjusts its answer to who is asking: patient, caregiver, science-literate adult, medical student or healthcare worker.**
It is Qwen3-4B, fully fine-tuned on medical conversations. It holds multi-turn conversations, supports thinking and non-thinking modes.
![Scores for the base model, SFT and RL100 in both modes, graded by GPT-6 Luna](assets/launch-scorecard.png)
| HealthBench Consensus, 1,000 English prompts | Qwen3-4B (base) | After fine-tuning (SFT) | **Med Advisor (RL100)** |
|---|---:|---:|---:|
| Non-thinking | 34.5% | 40.7% | **54.4%** |
| Thinking | 32.0% | 47.9% | **59.9%** |
RL100 is the released model: the reinforcement-learning (RL) training checkpoint after 100 updates. Same system message and sampling settings for every model. Graded by GPT-6 Luna, not the official HealthBench grader, so compare the columns with each other and not with published HealthBench numbers. [Details](#evaluation).
**This model has not been clinically validated.** It is for education and research. It can be wrong, and it must not be used for diagnosis, prescribing, personal dosing, treatment selection or interpreting an individual's medical records.
<!-- Before publishing: confirm the uploaded weights are the RL100 checkpoint, run the quick-start snippet against them in both modes, and add author and citation details. This comment does not show on the rendered page. -->
[Three examples](#start-with-three-conversations) · [Scope](#scope) · [Quick start](#quick-start) · [All examples](#example-conversations) · [RL Recipe](#rl-recipe) · [Evaluation](#evaluation) · [Limitations](#intended-use-and-limitations)
## Start with three conversations
- **A number explained in plain terms:** [The advert says 50% fewer heart attacks](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n09-relative-vs-absolute-risk.md). The model turns a 50% relative reduction at a 4% baseline risk into absolute numbers, then writes a version to say to a patient.
- **A correction changes the answer:** [Metformin or metoprolol?](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t02-metformin-or-metoprolol.md) The user checks the bottle in turn three, and the model updates its explanation.
- **A follow-up changes the urgency:** [An eGFR of 42 on a weekend, then new confusion](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t03-egfr-then-confusion.md). When the user adds acute symptoms, the next reply leads with escalation.
## Scope
| | |
|---|---|
| **Audiences (5)** | Curious patient · Caregiver · Science-literate adult · Medical student · Healthcare worker |
| **Kinds of request (6)** | Explanation, mechanism and evidence · Lab, test and risk interpretation · Medication and numerical reasoning · Self-care and next steps · Safety escalation · Misinformation correction |
| **Domains (16)** | General medicine · Oncology · Laboratory and diagnostic medicine · Medication safety · Cardiovascular · Infectious disease · Endocrinology · Neurology · Respiratory · Musculoskeletal · Gastroenterology · Dermatology · Genetics and genomics · Nephrology and urology · Rare disease · Mental health |
| **Modes** | Thinking (reasons first, then answers) and non-thinking, switched with `enable_thinking` |
| **Language** | English |
The audience changes the depth and vocabulary of an answer. It does not change the rules: the model is trained to explain, to stay out of personal clinical decisions for every audience, and to put emergency escalation first.
## Quick start
```bash
pip install "transformers>=4.57" accelerate safetensors
```
The BF16 weights need about 8 GB of memory, plus room for the context.
```python
import torch
from transformers import AutoModelForCausalLM, AutoTokenizer
MODEL_ID = "vmal/med-advisor-conversation-4B"
THINKING = False # True: the model reasons before the visible answer
tokenizer = AutoTokenizer.from_pretrained(MODEL_ID)
model = AutoModelForCausalLM.from_pretrained(MODEL_ID, dtype=torch.bfloat16, device_map="auto").eval()
system_message = (
"You are Med Advisor, a clear, evidence-aware medical and scientific "
"explainer. Use the native reasoning channel when thinking is enabled, and "
"keep the visible answer self-contained. Give useful general education with "
"calibrated uncertainty. Do not diagnose, prescribe, select patient-specific "
"treatment, provide patient-specific dosing, interpret personal medical data "
"or genetic variants as clinical conclusions, or replace clinician judgment. "
"Escalate emergencies immediately."
)
messages = [
{"role": "system", "content": system_message},
{"role": "user", "content": "My mom's lab report says eGFR 42. What does that number mean?"},
]
inputs = tokenizer.apply_chat_template(
messages, tokenize=True, add_generation_prompt=True,
enable_thinking=THINKING, return_dict=True, return_tensors="pt",
).to(model.device)
with torch.inference_mode():
output = model.generate(
**inputs, do_sample=True, top_k=20, max_new_tokens=8192,
temperature=0.6 if THINKING else 0.7,
top_p=0.95 if THINKING else 0.8,
)
text = tokenizer.decode(output[0, inputs["input_ids"].shape[-1]:], skip_special_tokens=True)
answer = text.split("</think>")[-1].strip()
print(answer)
messages.append({"role": "assistant", "content": answer}) # keep only the visible answer in history
```
Three things matter for getting the behavior shown here:
- **Use this system message.** The model was trained and evaluated with it.
- **Keep only visible answers in the conversation history**, never the reasoning.
- **Cap `max_new_tokens` in thinking mode.** The model occasionally loops while reasoning. If an answer does not finish, retry in non-thinking mode.
## Example conversations
Twenty selected conversations show how the model answers five audiences across six kinds of request, in thinking and non-thinking mode. [Browse all examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md).
| Audience | Thinking | Non-thinking |
|---|---|---|
| Curious patient | [Back pain with cancer is only urgent at 10 out of 10?](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t01-cancer-back-pain.md)<br>[Metformin or metoprolol? The user checks the bottle](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t02-metformin-or-metoprolol.md) | [Facial swelling and chest veins: ER tonight or doctor next week?](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n01-facial-swelling-er.md)<br>[Six turns on why a trial statistic is not a personal prognosis](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n02-trial-statistics-prognosis.md) |
| Caregiver | [An eGFR of 42 on a weekend, then new confusion](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t03-egfr-then-confusion.md)<br>[Seizure first aid, then a version for the fridge door](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t04-seizure-first-aid.md) | [Alendronate "with food to protect her stomach"](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n03-alendronate-instructions.md)<br>[A symptom timeline to bring to the appointment](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n04-symptom-timeline.md) |
| Science-literate adult | [From sensitivity and specificity to the chance a positive is real](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t05-positive-predictive-value.md)<br>[Low-dose naltrexone for Hashimoto's: how good is the evidence?](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t06-low-dose-naltrexone.md) | [mEq/L and mmol/L, and why valence matters](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n05-meq-and-mmol.md)<br>["Caregiver stress raises cortisol 300% and destroys the brain"](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n06-caregiver-stress-cortisol.md) |
| Medical student | [Lorazepam before an MRI "eliminates anxiety with no risks"?](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t07-lorazepam-before-mri.md)<br>[Why a rare-disease trial must name its population and endpoint](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t08-rare-disease-trials.md) | [Inflammation versus infection, then the receptor-to-cytokine pathway](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n07-inflammation-vs-infection.md)<br>[A medical student wants a levothyroxine dose to request for a parent](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n08-levothyroxine-dose.md) |
| Healthcare worker | ["After 24 hours the testis is dead, book it as outpatient"](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t09-testicular-torsion-note.md)<br>[Predictive versus prognostic biomarkers](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t10-predictive-vs-prognostic.md) | [The advert says 50% fewer heart attacks](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n09-relative-vs-absolute-risk.md)<br>[A "screening" CA 19-9 of 45 in a healthy 55-year-old](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n10-ca-19-9-screening.md) |
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*
One short excerpt. A caregiver has just been given seizure first-aid steps and asks for something shorter:
> **User:** That makes sense, thank you — so no holding her down, nothing in her mouth, and time it. Can you give me a really short version I could write on a note for the fridge or repeat to another family member?
>
> **Med Advisor:**
>
> **Fridge note:**
> - Don’t hold her down.
> - Don’t put anything in her mouth.
> - Clear hard objects.
> - If on the floor, turn her on her side if safe.
> - Time it.
> - Call emergency if seizure lasts more than 5 minutes, or she has another seizure without waking.
> - Follow her seizure action plan.
## RL Recipe
- [RL training recipe and code](https://github.com/vimalKeshu/med-advisor-conversation-4B/tree/main/rl-training): architecture, simulated conversations, grading rubrics, reward calculation, and policy updates.
## Evaluation
![HealthBench Consensus scores for the base model, SFT and the RL training checkpoints](assets/healthbench.png)
**Reading the chart.** Baseline is Qwen3-4B before any training. SFT is the model after supervised fine-tuning. RL25, RL50, RL75 and RL100 are checkpoints saved during reinforcement-learning training, after 25, 50, 75 and 100 updates. RL100 is the released model. T is thinking mode and NT is non-thinking mode.
**What was run.** 1,000 English prompts drawn from the 3,671-example HealthBench Consensus set, stratified by theme. Each model answered once per prompt with the system message and sampling settings above. Only the visible answer was graded. The benchmark allowed up to 32,768 tokens per reply, more than the quick-start cap. The grader was GPT-6 Luna; the official HealthBench grader is a different model, so these scores are not comparable with published HealthBench results. [Full protocol, intervals and saved results](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/evaluation/README.md).
| Stage | What it is | Non-thinking | Thinking |
|---|---|---:|---:|
| Baseline | Qwen3-4B, before training | 34.5% | 32.0% |
| SFT | After supervised fine-tuning | 40.7% | 47.9% |
| RL25 | RL training checkpoint, 25 updates | 41.9% | 51.8% |
| RL50 | RL training checkpoint, 50 updates | 48.9% | 55.6% |
| RL75 | RL training checkpoint, 75 updates | 51.5% | 56.9% |
| **RL100** | **RL training checkpoint, 100 updates (this model)** | **54.4%** | **59.9%** |
The score rises at every RL checkpoint in both modes. The 95% intervals are about ±2.5 points; for RL100 they are 51.8 to 56.8 (non-thinking) and 57.4 to 62.4 (thinking).
Against the base model in the same mode, RL100 gains 19.9 points without thinking (paired 95% interval 17.4 to 22.3) and 28.0 points with thinking (25.5 to 30.5).
**By theme** (mean score per prompt):
| Theme | Base, non-thinking | Med Advisor, non-thinking | Med Advisor, thinking |
|---|---:|---:|---:|
| Emergency referrals | 22.0% | 55.3% | 65.9% |
| Context seeking | 22.5% | 50.5% | 58.1% |
| Communication | 10.8% | 32.8% | 42.6% |
| Hedging | 51.2% | 70.1% | 77.0% |
| Global health | 62.4% | 79.8% | 82.4% |
| Health data tasks | 41.7% | 50.9% | 49.1% |
| Complex responses | 21.0% | 27.3% | 25.6% |
**Reading these numbers.** Med Advisor also writes much shorter answers: a median of 157 to 208 words against about 350 for the base model. The gain is not only brevity. On prompts where both models wrote answers of similar length (within 25%), it was 18.3 points without thinking (194 prompts) and 16.1 points with thinking (64 prompts).
## Intended use and limitations
**Use it for** learning and explaining: what a term or result means, how a mechanism works, how strong the evidence is, what to ask a clinician, and when something is an emergency. It is also a research artifact for studying conversation-level reinforcement learning.
**Do not use it for** diagnosis, prescribing, dosing for a specific person, choosing a treatment, or interpreting someone's records. It is trained to decline these, but it will not always do so.
## License
Apache 2.0, the same license as the base model.
## Citation
If you use this checkpoint, please cite the model page.

28
added_tokens.json Normal file
View File

@@ -0,0 +1,28 @@
{
"</think>": 151668,
"</tool_call>": 151658,
"</tool_response>": 151666,
"<think>": 151667,
"<tool_call>": 151657,
"<tool_response>": 151665,
"<|box_end|>": 151649,
"<|box_start|>": 151648,
"<|endoftext|>": 151643,
"<|file_sep|>": 151664,
"<|fim_middle|>": 151660,
"<|fim_pad|>": 151662,
"<|fim_prefix|>": 151659,
"<|fim_suffix|>": 151661,
"<|im_end|>": 151645,
"<|im_start|>": 151644,
"<|image_pad|>": 151655,
"<|object_ref_end|>": 151647,
"<|object_ref_start|>": 151646,
"<|quad_end|>": 151651,
"<|quad_start|>": 151650,
"<|repo_name|>": 151663,
"<|video_pad|>": 151656,
"<|vision_end|>": 151653,
"<|vision_pad|>": 151654,
"<|vision_start|>": 151652
}

3
assets/healthbench.png Normal file
View File

@@ -0,0 +1,3 @@
version https://git-lfs.github.com/spec/v1
oid sha256:f9401ebe9e03e153bd0577b168b43bd8ea822695df8241947a796088dc4cde16
size 167942

3
assets/launch-conversation.png Normal file
View File

@@ -0,0 +1,3 @@
version https://git-lfs.github.com/spec/v1
oid sha256:47e0bbdec9bc21c9d974b95cc524da24e2aa42bbe56015c74f11d80d51e95bd3
size 101341

BIN
assets/launch-scorecard.png Normal file
View File

Binary file not shown.
Side by Side

After

Width:  |  Height:  |  Size: 61 KiB

89
chat_template.jinja Normal file
View File

@@ -0,0 +1,89 @@
{%- if tools %}
{{- '<|im_start|>system\n' }}
{%- if messages[0].role == 'system' %}
{{- messages[0].content + '\n\n' }}
{%- endif %}
{{- "# Tools\n\nYou may call one or more functions to assist with the user query.\n\nYou are provided with function signatures within <tools></tools> XML tags:\n<tools>" }}
{%- for tool in tools %}
{{- "\n" }}
{{- tool | tojson }}
{%- endfor %}
{{- "\n</tools>\n\nFor each function call, return a json object with function name and arguments within <tool_call></tool_call> XML tags:\n<tool_call>\n{\"name\": <function-name>, \"arguments\": <args-json-object>}\n</tool_call><|im_end|>\n" }}
{%- else %}
{%- if messages[0].role == 'system' %}
{{- '<|im_start|>system\n' + messages[0].content + '<|im_end|>\n' }}
{%- endif %}
{%- endif %}
{%- set ns = namespace(multi_step_tool=true, last_query_index=messages|length - 1) %}
{%- for message in messages[::-1] %}
{%- set index = (messages|length - 1) - loop.index0 %}
{%- if ns.multi_step_tool and message.role == "user" and message.content is string and not(message.content.startswith('<tool_response>') and message.content.endswith('</tool_response>')) %}
{%- set ns.multi_step_tool = false %}
{%- set ns.last_query_index = index %}
{%- endif %}
{%- endfor %}
{%- for message in messages %}
{%- if message.content is string %}
{%- set content = message.content %}
{%- else %}
{%- set content = '' %}
{%- endif %}
{%- if (message.role == "user") or (message.role == "system" and not loop.first) %}
{{- '<|im_start|>' + message.role + '\n' + content + '<|im_end|>' + '\n' }}
{%- elif message.role == "assistant" %}
{%- set reasoning_content = '' %}
{%- if message.reasoning_content is string %}
{%- set reasoning_content = message.reasoning_content %}
{%- else %}
{%- if '</think>' in content %}
{%- set reasoning_content = content.split('</think>')[0].rstrip('\n').split('<think>')[-1].lstrip('\n') %}
{%- set content = content.split('</think>')[-1].lstrip('\n') %}
{%- endif %}
{%- endif %}
{%- if loop.index0 > ns.last_query_index %}
{%- if loop.last or (not loop.last and reasoning_content) %}
{{- '<|im_start|>' + message.role + '\n<think>\n' + reasoning_content.strip('\n') + '\n</think>\n\n' + content.lstrip('\n') }}
{%- else %}
{{- '<|im_start|>' + message.role + '\n' + content }}
{%- endif %}
{%- else %}
{{- '<|im_start|>' + message.role + '\n' + content }}
{%- endif %}
{%- if message.tool_calls %}
{%- for tool_call in message.tool_calls %}
{%- if (loop.first and content) or (not loop.first) %}
{{- '\n' }}
{%- endif %}
{%- if tool_call.function %}
{%- set tool_call = tool_call.function %}
{%- endif %}
{{- '<tool_call>\n{"name": "' }}
{{- tool_call.name }}
{{- '", "arguments": ' }}
{%- if tool_call.arguments is string %}
{{- tool_call.arguments }}
{%- else %}
{{- tool_call.arguments | tojson }}
{%- endif %}
{{- '}\n</tool_call>' }}
{%- endfor %}
{%- endif %}
{{- '<|im_end|>\n' }}
{%- elif message.role == "tool" %}
{%- if loop.first or (messages[loop.index0 - 1].role != "tool") %}
{{- '<|im_start|>user' }}
{%- endif %}
{{- '\n<tool_response>\n' }}
{{- content }}
{{- '\n</tool_response>' }}
{%- if loop.last or (messages[loop.index0 + 1].role != "tool") %}
{{- '<|im_end|>\n' }}
{%- endif %}
{%- endif %}
{%- endfor %}
{%- if add_generation_prompt %}
{{- '<|im_start|>assistant\n' }}
{%- if enable_thinking is defined and enable_thinking is false %}
{{- '<think>\n\n</think>\n\n' }}
{%- endif %}
{%- endif %}

68
config.json Normal file
View File

@@ -0,0 +1,68 @@
{
"architectures": [
"Qwen3ForCausalLM"
],
"attention_bias": false,
"attention_dropout": 0.0,
"bos_token_id": 151643,
"dtype": "float32",
"eos_token_id": 151645,
"head_dim": 128,
"hidden_act": "silu",
"hidden_size": 2560,
"initializer_range": 0.02,
"intermediate_size": 9728,
"layer_types": [
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention",
"full_attention"
],
"max_position_embeddings": 40960,
"max_window_layers": 36,
"model_type": "qwen3",
"num_attention_heads": 32,
"num_hidden_layers": 36,
"num_key_value_heads": 8,
"rms_norm_eps": 1e-06,
"rope_scaling": null,
"rope_theta": 1000000,
"sliding_window": null,
"tie_word_embeddings": true,
"transformers_version": "4.57.1",
"use_cache": true,
"use_sliding_window": false,
"vocab_size": 151936
}

56
examples/README.md Normal file
View File

@@ -0,0 +1,56 @@
# Example conversations
Twenty conversations with Med Advisor: ten in thinking mode and ten in non-thinking mode. Each set has two conversations for each of the five audiences the model is tuned for, and covers six kinds of request.
Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.
## Find a conversation
Rows are who is asking, ordered by how much medical knowledge they bring. Columns are what they want. T is thinking mode, N is non-thinking mode.
| Audience | Explanation & evidence | Lab, test & risk | Medication & numbers | Self-care & next steps | Safety escalation | Misinformation |
|---|---|---|---|---|---|---|
| **Curious patient**<br>basic knowledge | · | [N02](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n02-trial-statistics-prognosis.md) | · | [T02](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t02-metformin-or-metoprolol.md) | [N01](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n01-facial-swelling-er.md) | [T01](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t01-cancer-back-pain.md) |
| **Caregiver**<br>basic knowledge | · | · | [N03](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n03-alendronate-instructions.md) | [T04](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t04-seizure-first-aid.md) [N04](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n04-symptom-timeline.md) | [T03](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t03-egfr-then-confusion.md) | · |
| **Science-literate adult**<br>intermediate knowledge | · | [T05](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t05-positive-predictive-value.md) | [T06](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t06-low-dose-naltrexone.md) [N05](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n05-meq-and-mmol.md) | · | · | [N06](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n06-caregiver-stress-cortisol.md) |
| **Medical student**<br>advanced knowledge | [T08](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t08-rare-disease-trials.md) [N07](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n07-inflammation-vs-infection.md) | · | [N08](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n08-levothyroxine-dose.md) | · | · | [T07](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t07-lorazepam-before-mri.md) |
| **Healthcare worker**<br>advanced knowledge | [T10](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t10-predictive-vs-prognostic.md) | [N10](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n10-ca-19-9-screening.md) | [N09](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n09-relative-vs-absolute-risk.md) | · | [T09](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t09-testicular-torsion-note.md) | · |
## Thinking mode
The model reasons before it answers. Only the visible answers are shown.
| | Conversation | Audience | Intent | Turns |
|---|---|---|---|---:|
| T01 | [Back pain with cancer is only urgent at 10 out of 10?](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t01-cancer-back-pain.md) | Curious patient | Misinformation | 2 |
| T02 | [Metformin or metoprolol? The user checks the bottle](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t02-metformin-or-metoprolol.md) | Curious patient | Self-care & next steps | 3 |
| T03 | [An eGFR of 42 on a weekend, then new confusion](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t03-egfr-then-confusion.md) | Caregiver | Safety escalation | 2 |
| T04 | [Seizure first aid, then a version for the fridge door](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t04-seizure-first-aid.md) | Caregiver | Self-care & next steps | 2 |
| T05 | [From sensitivity and specificity to the chance a positive is real](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t05-positive-predictive-value.md) | Science-literate adult | Lab, test & risk | 2 |
| T06 | [Low-dose naltrexone for Hashimoto's: how good is the evidence?](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t06-low-dose-naltrexone.md) | Science-literate adult | Medication & numbers | 2 |
| T07 | [Lorazepam before an MRI "eliminates anxiety with no risks"?](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t07-lorazepam-before-mri.md) | Medical student | Misinformation | 3 |
| T08 | [Why a rare-disease trial must name its population and endpoint](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t08-rare-disease-trials.md) | Medical student | Explanation & evidence | 2 |
| T09 | ["After 24 hours the testis is dead, book it as outpatient"](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t09-testicular-torsion-note.md) | Healthcare worker | Safety escalation | 2 |
| T10 | [Predictive versus prognostic biomarkers](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t10-predictive-vs-prognostic.md) | Healthcare worker | Explanation & evidence | 2 |
## Non-thinking mode
The model answers directly.
| | Conversation | Audience | Intent | Turns |
|---|---|---|---|---:|
| N01 | [Facial swelling and chest veins: ER tonight or doctor next week?](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n01-facial-swelling-er.md) | Curious patient | Safety escalation | 3 |
| N02 | [Six turns on why a trial statistic is not a personal prognosis](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n02-trial-statistics-prognosis.md) | Curious patient | Lab, test & risk | 6 |
| N03 | [Alendronate "with food to protect her stomach"](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n03-alendronate-instructions.md) | Caregiver | Medication & numbers | 2 |
| N04 | [A symptom timeline to bring to the appointment](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n04-symptom-timeline.md) | Caregiver | Self-care & next steps | 2 |
| N05 | [mEq/L and mmol/L, and why valence matters](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n05-meq-and-mmol.md) | Science-literate adult | Medication & numbers | 2 |
| N06 | ["Caregiver stress raises cortisol 300% and destroys the brain"](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n06-caregiver-stress-cortisol.md) | Science-literate adult | Misinformation | 3 |
| N07 | [Inflammation versus infection, then the receptor-to-cytokine pathway](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n07-inflammation-vs-infection.md) | Medical student | Explanation & evidence | 2 |
| N08 | [A medical student wants a levothyroxine dose to request for a parent](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n08-levothyroxine-dose.md) | Medical student | Medication & numbers | 2 |
| N09 | [The advert says 50% fewer heart attacks](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n09-relative-vs-absolute-risk.md) | Healthcare worker | Medication & numbers | 2 |
| N10 | [A "screening" CA 19-9 of 45 in a healthy 55-year-old](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n10-ca-19-9-screening.md) | Healthcare worker | Lab, test & risk | 2 |
## Generation settings
- Thinking: temperature 0.6, top-p 0.95, top-k 20
- Non-thinking: temperature 0.7, top-p 0.8, top-k 20

78
examples/non-thinking/n01-facial-swelling-er.md Normal file
View File

@@ -0,0 +1,78 @@
# Facial swelling and chest veins: ER tonight or doctor next week?
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Curious patient | Basic | Safety escalation | Possible superior vena cava syndrome | Non-thinking | 3 |
**Highlights:** Instruction in the first sentence · Holds urgency under pressure · Flexible where it is safe
---
### Turn 1
**User**
> I've been having some swelling in my face and neck, and my veins on my chest look more prominent. I also feel short of breath when I bend over. I read online that this could be superior vena cava syndrome from a tumor. Can you tell me what to do? Should I go to the ER right now or can I wait to see my doctor next week?
**Med Advisor**
**Go to the emergency department now.** This combination of facial/neck swelling, prominent chest veins, and shortness of breath when bending over can signal a serious problem — most urgently, superior vena cava (SVC) syndrome, which can be life-threatening. Do not wait for a routine appointment.
**Why this is urgent:** SVC syndrome occurs when pressure builds up in the superior vena cava, the large vein returning blood from the head and arms to the heart. Causes include tumors (often lung, but also other cancers), blood clots, or other blockages. It can cause swelling of the face, neck, and arms, distended neck veins, and difficulty breathing — especially when bending over or lying flat. It can worsen quickly and, in some cases, become dangerous.
**What to do right now:**
- **Call emergency services or go to the nearest ER immediately.** If you are short of breath now, that is an emergency.
- Tell them clearly: "I have facial and neck swelling, prominent chest veins, and shortness of breath when I bend over." That description helps them prioritize.
- Do not drive yourself if you are short of breath or feel unwell.
- Do not try to manage this at home or wait for a callback.
**Important:** I can't diagnose you, and I can't tell you what's causing this. But the symptoms you describe are not something to monitor at home. Emergency evaluation is the right step.
If you are already in the ER or being seen, tell the medical team about all of these symptoms so they can assess you promptly.
### Turn 2
**User**
> I feel basically okay when I'm sitting still, so is it really necessary to go in tonight, or would first thing in the morning be fine?
**Med Advisor**
**Go in tonight, not first thing in the morning.** Even though you feel okay sitting still, the symptoms you described — facial/neck swelling, prominent chest veins, and shortness of breath when bending over — are exactly the kind of thing that can worsen quickly, and they can become dangerous. "Feeling okay right now" does not rule out a serious cause like SVC syndrome or a blood clot.
**Why timing matters:** These symptoms can progress over hours, not days. If you wait until morning, it may be too late if the problem is severe. The ER can evaluate you, check your breathing, and start treatment if needed.
**What to do tonight:**
- **Go to the ER now** or call emergency services.
- Tell them: "I have facial and neck swelling, prominent chest veins, and shortness of breath when I bend over."
- If you are short of breath, feel faint, or have trouble breathing at rest, that is an emergency — call for help immediately.
**If you can't get to the ER tonight** (e.g., no transportation, or you're alone and unsure), call your doctor or an urgent care line and describe your symptoms. They may advise you to go in, and if they say to wait, they should give you clear instructions on when to seek emergency care.
I can't assess your situation or tell you it's safe to wait. Given what you've described, the safest choice is to be evaluated tonight.
### Turn 3
**User**
> If the ER is only about ten minutes away and I'm not short of breath while sitting, is it okay to have someone drive me rather than calling an ambulance?
**Med Advisor**
**Yes — having someone drive you to the ER is reasonable if you are not short of breath while sitting, and the ER is only about ten minutes away.** That said, the priority is still to go in tonight, not to wait for morning.
**What to keep in mind:**
- **Call ahead if you can** to the ER so they can prepare for you. If you're not short of breath at rest, they may be able to triage you appropriately.
- **Do not drive yourself** if you feel any shortness of breath, dizziness, or weakness — that could be an emergency.
- **Have someone with you** to help you and stay alert, especially if you feel unwell or have trouble breathing.
- **Tell the ER staff** exactly what you described: facial and neck swelling, prominent chest veins, and shortness of breath when bending over.
**If anything changes while you're on the way** — you start feeling short of breath, you feel faint, or you have trouble breathing — tell the driver and go to the nearest emergency department immediately. Don't wait to see if it passes.
I can't assess your situation or tell you it's safe to wait. But given the symptoms you've described, being evaluated tonight is the right step. If you're unsure or feel worse, treat it as an emergency and call for help.
---
[All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [N02 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n02-trial-statistics-prognosis.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

150
examples/non-thinking/n02-trial-statistics-prognosis.md Normal file
View File

@@ -0,0 +1,150 @@
# Six turns on why a trial statistic is not a personal prognosis
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Curious patient | Basic | Lab, test and risk interpretation | Cancer trial endpoints | Non-thinking | 6 |
**Highlights:** Tracks a correction mid-conversation · Refuses to invent a survival number · Summarizes on request
---
### Turn 1
**User**
> Explain response rate versus overall survival.
**Med Advisor**
**Response rate (objective response rate, ORR)** and **overall survival (OS)** are two different endpoints used in cancer trials.
**Response rate** measures how often a treatment shrinks or eliminates measurable tumors. It's usually reported as a percentage: e.g., "30% response rate." It reflects *how well the tumor responds* and is often used early in a trial.
**Overall survival** measures how long patients live after starting treatment, compared with a control group. It reflects *how long the treatment keeps people alive*. It's generally considered the most clinically meaningful endpoint because it captures the real-world benefit.
**Key differences:**
- **What it measures:** ORR = tumor response; OS = time-to-death.
- **Timing:** ORR can be seen quickly; OS takes longer to show.
- **What it can miss:** A treatment can shrink tumors without improving survival (e.g., a drug that works on one biomarker but doesn't affect the biology driving death).
- **What it can overstate:** A high ORR with little survival benefit may still be reported as "successful."
**Why both matter:** A trial might show a good response rate but no clear survival gain, or vice versa. Regulators and clinicians often weigh both, though OS is typically the primary endpoint for approval decisions in serious diseases.
**Important caveat:** These are trial-level statistics, not predictions for any individual. They describe groups, and outcomes can vary widely between people. If you're asking about a specific treatment or your own situation, a clinician can interpret what these numbers mean in context.
### Turn 2
**User**
> Okay, that makes sense. But I have a specific situation: a trial's response rate was 70 percent, so can you predict my five-year survival from that?
**Med Advisor**
No — a trial's response rate of 70% cannot predict your individual five-year survival.
Here's why:
- **Response rate ≠ survival.** A 70% response rate means 70% of the patients in that trial had their tumors shrink or disappear on that treatment. It says nothing about how long those patients lived. Some responded but still died of other causes; some didn't respond but lived longer.
- **It's a group statistic.** The 70% applies to the patients studied in that trial, not to you personally. Your outcome depends on many factors — your cancer type, stage, biomarkers, other health conditions, and how the treatment is delivered.
- **Survival depends on more than response.** Survival is influenced by the underlying disease, the treatment's effect on the biology driving death, and other clinical factors. A high response rate with little survival benefit has been documented.
- **Even trial-level survival estimates are uncertain.** Reported survival figures come from a specific population and time frame, and they may not generalize to everyone.
So the response rate is one data point, not a forecast of your survival. If you're asking about a specific treatment or your own prognosis, that should be discussed with your treating oncologist, who can interpret the results in your particular context.
### Turn 3
**User**
> Actually, I need to correct myself — the 70 percent I mentioned was the disease-control rate, not the response rate. Does that change anything about what you just said?
**Med Advisor**
Yes — that changes the meaning, but not the core point.
**Disease-control rate (DCR)** is a broader endpoint than response rate. It generally includes:
- **Complete response** (no detectable disease)
- **Partial response** (tumor shrinkage)
- **Stable disease** (no significant growth)
So a 70% DCR means 70% of patients in the trial had their disease controlled — either shrinking, stable, or absent — in the measured time frame. It's a softer, more inclusive measure than ORR.
**Does it change what I said?**
- **No, the same caution applies.** A 70% DCR still does not predict your individual five-year survival. It describes the group studied, not you.
- **It may be more informative than ORR** in some contexts, because it captures more patients (including those whose disease stabilized).
- **It still doesn't tell you how long you'll live.** Disease control and survival are related but distinct. Some patients with controlled disease still die of other causes; some with no control live longer.
So the correction matters for *what the number means*, but the bottom line remains: a trial-level statistic like a 70% DCR is not a personal survival forecast. Your oncologist can interpret these results in your specific situation.
### Turn 4
**User**
> One more thing — the study was in untreated patients, but I've already had two prior treatments. Does that matter for whether those numbers apply to me?
**Med Advisor**
Yes — that's an important distinction, and it's a reasonable thing to raise with your oncologist.
**Why it matters:**
- **The trial population may not match you.** If the study was in patients who had *not* received prior treatment, then the response or disease-control figures describe that specific group. Patients who have already had two treatments are a different population, and the study's results may not directly apply to them.
- **Prior treatments can change the biology and the expected benefit.** Subsequent lines of therapy often target different mechanisms or are given with different goals. A treatment that worked well early may behave differently later.
- **What the numbers do and don't tell you:** They still don't predict your individual survival. They're trial-level statistics, and they don't account for your specific cancer, prior therapies, or current health.
**What's more useful to ask your oncologist:**
- Is there any evidence or data relevant to patients who have had prior treatments?
- How do these results compare with what's known for my specific cancer type and situation?
- What's the goal of any next treatment, and what are the realistic expectations?
So the correction to "response rate" → "disease-control rate" matters for what the number means, and the fact that you've already had two treatments matters for whether the study's results are directly applicable to you. Your oncologist can help interpret that in your specific context.
### Turn 5
**User**
> I understand all that, but I still want a number. Give me one exact personal probability anyway — just a percent for my five-year survival.
**Med Advisor**
I can't give you a personal survival percentage, and I want to be straight with you about why — not just give you a number that sounds like a prediction.
**Why I can't provide one:**
- **No valid input.** A five-year survival figure requires your specific cancer type, stage, biomarkers, prior treatments, and other clinical details. I don't have those, and even with them, a single number would be a guess dressed up as a fact.
- **Trial statistics aren't personal forecasts.** The 70% DCR applies to a specific group of patients in a specific trial. It cannot be converted into your individual survival probability without knowing how much you differ from that group.
- **A fabricated number would be misleading.** If I gave you a percentage, it could be interpreted as a real prognosis, which could cause unnecessary worry or false reassurance.
**What I can offer:**
- Your oncologist can give you a more meaningful estimate based on your actual situation — that's the right source.
- If you'd like, I can explain how oncologists generally think about prognosis, or what questions to ask your care team.
If you're feeling anxious about this, that's understandable, and talking with your oncologist about your specific case is the best next step.
### Turn 6
**User**
> Fine. Then just summarize for me why that 70 percent statistic can't be transferred directly to me.
**Med Advisor**
Here's a summary of why the 70% statistic can't be directly transferred to you:
- **It's a group statistic, not a personal prediction.** The 70% describes the patients studied in that trial — a specific population, not you.
- **It measures disease control, not survival.** Even a 70% disease-control rate doesn't tell you how long anyone in that group lived.
- **Your situation may differ.** You've already had two treatments, which can change the biology and expected benefit of any subsequent treatment.
- **It doesn't account for your individual factors.** Your cancer type, stage, biomarkers, and other health details matter and aren't captured by the trial number.
- **Even trial-level survival estimates are uncertain.** They come from a specific time frame and population, and they may not generalize to everyone.
So the 70% is useful context for understanding that trial's results, but it can't be used to predict your individual five-year survival. Your oncologist can interpret these results in your specific situation.
---
[← N01](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n01-facial-swelling-er.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [N03 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n03-alendronate-instructions.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

53
examples/non-thinking/n03-alendronate-instructions.md Normal file
View File

@@ -0,0 +1,53 @@
# Alendronate "with food to protect her stomach"
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Caregiver | Basic | Medication and numerical reasoning | Osteoporosis medication instructions | Non-thinking | 2 |
**Highlights:** Reverses a wrong instruction · Explains why · Checks the user's teach-back
---
### Turn 1
**User**
> My mother has been prescribed alendronate for osteoporosis. I've read she must take it with food to protect her stomach. How should she take it?
**Med Advisor**
For alendronate, the key is to take it **on an empty stomach** — not with food. Here's the general guidance:
- **Take it with a full glass of plain water** (usually 8–12 oz / 240–360 mL).
- **Wait at least 30 minutes** before eating, drinking anything else, or taking other medications.
- **Take it as directed** by her prescriber — typically once daily, or as specified.
- **Sit or stand upright** for at least 30 minutes after taking it. Do not lie down, and avoid taking it with milk, calcium supplements, antacids, or other bone or stomach medications.
Why the empty-stomach rule: alendronate works best on an empty stomach, and food, especially calcium or antacids, can reduce its absorption.
**Important:** She should not take it with food, milk, or other medications as a general rule — but the exact schedule and any exceptions should come from her prescriber or pharmacist. If she has trouble swallowing, has had stomach upset, or is unsure about the regimen, she should ask her prescriber or pharmacist for personalized instructions.
If she develops severe stomach pain, trouble swallowing, or other concerning symptoms after taking it, she should contact her clinician promptly.
### Turn 2
**User**
> Thanks — I had it backwards then, so I'll correct what I tell her. Just so I have it straight to repeat to her: plain water, a full glass, wait 30 minutes before anything else, and stay upright for those 30 minutes.
**Med Advisor**
Yes — that's a solid summary to repeat to her. To make sure it's accurate:
- **Plain water**, a full glass (about 8–12 oz / 240–360 mL).
- **Take it on an empty stomach**, wait **30 minutes** before eating, drinking anything else, or taking other medications.
- **Stay upright** for at least **30 minutes** after taking it — don't lie down.
- Follow the specific instructions her prescriber gave her, since doses and schedules vary.
One small caveat: if she has any trouble swallowing or has had stomach upset, she should confirm the plan with her prescriber or pharmacist, since those situations can affect how it's taken. Otherwise, your summary is correct.
---
[← N02](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n02-trial-statistics-prognosis.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [N04 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n04-symptom-timeline.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

98
examples/non-thinking/n04-symptom-timeline.md Normal file
View File

@@ -0,0 +1,98 @@
# A symptom timeline to bring to the appointment
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Caregiver | Basic | Self-care and next steps | Appointment preparation | Non-thinking | 2 |
**Highlights:** Practical preparation · Produces a fill-in template · Keeps the emergency criteria attached
---
### Turn 1
**User**
> My mom is 72 and has been feeling off for a few days. She has a history of high blood pressure and mild kidney issues. I want to help her get ready for a doctor's appointment. How should I prepare a symptom timeline to bring to her doctor? What should I include, and how detailed should it be?
**Med Advisor**
Here's a practical way to build a symptom timeline for her doctor.
**What to include:**
- **When symptoms started** and how long they've lasted (days, weeks).
- **What the symptoms are** — a short list, e.g., fatigue, dizziness, nausea, decreased urination, swelling, confusion.
- **How severe each symptom is** — mild, moderate, severe, or "worse than usual."
- **What makes it better or worse** — rest, fluids, food, position, activity.
- **Any new medications or changes** — including doses, new drugs, or missed doses.
- **Her blood pressure readings** if you have a home monitor, plus any kidney-related concerns.
- **Other health conditions** and relevant medical history.
- **Who else is involved** — family, caregivers, or other doctors.
**How detailed should it be?**
Keep it concise but complete. A one-page summary is usually enough. Be honest about what you don't know — that's useful information. You don't need to record every minute detail; focus on the pattern and timing.
**Practical tips:**
- Write it down or record a short voice note; both help the doctor.
- Bring a list of her current medications and doses.
- Note any recent hospital visits, tests, or specialist appointments.
- If she has a fever, chest pain, severe weakness, confusion, or trouble breathing, seek urgent care rather than waiting for the appointment.
**Important:** I can't assess your mom's specific situation or diagnose her. If she has severe or worsening symptoms, especially breathing difficulty, chest pain, confusion, or fainting, treat it as an emergency and get her seen immediately.
Would you like help drafting a simple template you can use?
### Turn 2
**User**
> Yes, a simple template would really help. I can fill in when her symptoms started, what they are, and any blood pressure readings, and leave blanks for anything I’m not sure about.
**Med Advisor**
Here's a simple template you can fill in. It's one page, so you can keep it handy.
---
**Symptom Timeline — [Your Mom's Name]**
**When symptoms started:**
- [Date] — [how long it's lasted]
**What the symptoms are:**
- (List, e.g., fatigue, dizziness, nausea, less urination, swelling, confusion)
**How severe each symptom is:**
- [mild / moderate / severe / worse than usual]
**What makes it better or worse:**
- [rest, fluids, food, position, activity]
**Blood pressure readings (if you have a monitor):**
- [date] — [reading]
**Other relevant info:**
- Any new medications or dose changes
- Recent hospital visits, tests, or specialist appointments
- Other health conditions (e.g., high blood pressure, kidney issues)
- Who else is involved (family, caregivers, other doctors)
**What I'm not sure about:**
- [leave blank or note "unknown"]
---
**Tips:**
- You can write it down, record a voice note, or bring a phone photo.
- Bring a list of her current medications and doses.
- If she has severe or worsening symptoms — especially trouble breathing, chest pain, confusion, or fainting — seek urgent care rather than waiting for the appointment.
Would you like me to suggest how to organize this into a one-page handout or a simple note format?
---
[← N03](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n03-alendronate-instructions.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [N05 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n05-meq-and-mmol.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

75
examples/non-thinking/n05-meq-and-mmol.md Normal file
View File

@@ -0,0 +1,75 @@
# mEq/L and mmol/L, and why valence matters
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Science-literate adult | Intermediate | Medication and numerical reasoning | Electrolyte units | Non-thinking | 2 |
**Highlights:** Unit conversion · Confirms the user's hypothesis · Extends the rule to other ions
---
### Turn 1
**User**
> I'm reading a paper that reports a serum potassium of 4.2 mEq/L. I'm more used to mmol/L. Is there a conversion, and are they the same thing?
**Med Advisor**
Yes, they're the same thing — mEq/L and mmol/L are equivalent units for potassium concentration.
**Conversion:**
1 mEq/L = 1 mmol/L. So a serum potassium of **4.2 mEq/L is exactly 4.2 mmol/L**.
A few practical points:
- **Reference range** is often given in mmol/L (e.g., roughly 3.5–5.0 mmol/L), so 4.2 falls within the typical normal range.
- Potassium is reported in both units across labs, and the conversion is a simple 1:1 ratio.
- If you see a potassium value in both units, they're interchangeable for clinical interpretation.
One caveat: unit labels can occasionally be misread or inconsistently reported, but when both are mEq/L or both mmol/L, the number is identical. If you have the full lab report, the units are usually specified clearly. For any personal or patient-specific interpretation, a clinician or lab report should be consulted.
### Turn 2
**User**
> That makes sense — is the 1:1 ratio because potassium is monovalent, so mEq equals mmol times valence? Would that mean a divalent ion like calcium or magnesium wouldn't be a 1:1 conversion?
**Med Advisor**
Yes — that's exactly right.
**Why the 1:1 ratio:**
Potassium has a valence of +1. The formula for milliequivalents is:
**mEq = mmol × valence**
So for potassium:
**mEq = mmol × 1**
→ mEq/L = mmol/L
**For divalent ions (valence 2):**
Calcium and magnesium are both +2, so:
**mEq = mmol × 2**
Which means:
**1 mmol/L of calcium = 2 mEq/L**
**1 mmol/L of magnesium = 2 mEq/L**
So calcium and magnesium are **not** a 1:1 conversion — their mEq values are double their mmol values. That's why calcium and magnesium are often reported in mg/dL or mmol/L rather than mEq/L, and why a lab report's unit label matters for interpretation.
**Quick reference:**
- Potassium: 1:1 (monovalent)
- Calcium: 1 mmol = 2 mEq
- Magnesium: 1 mmol = 2 mEq
This distinction is important when comparing values across labs or units, especially in clinical settings where different units are used. For any specific lab report or patient interpretation, a clinician or the lab's documentation should guide the meaning.
---
[← N04](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n04-symptom-timeline.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [N06 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n06-caregiver-stress-cortisol.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

77
examples/non-thinking/n06-caregiver-stress-cortisol.md Normal file
View File

@@ -0,0 +1,77 @@
# "Caregiver stress raises cortisol 300% and destroys the brain"
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Science-literate adult | Intermediate | Misinformation correction | Chronic stress, evidence in humans | Non-thinking | 3 |
**Highlights:** Corrects an alarming claim with warmth · Answers precise challenges · Withdraws its own overstatement
---
### Turn 1
**User**
> I'm a full-time caregiver for my mom who has advanced dementia. I'm completely exhausted and overwhelmed. I read that caregiver stress can increase cortisol levels by 300% and that high cortisol directly causes permanent brain damage. Is that true? I'm scared I'm literally destroying my brain by being stressed all the time.
**Med Advisor**
I'm sorry you're carrying this — caregiving for advanced dementia is one of the most demanding roles in the world, and it's completely understandable to feel exhausted and scared. I want to address the specific claims you read, because they're not accurate in the way they're being presented.
**The "300% cortisol" claim:** I can't find a reliable source that says cortisol rises by 300% in caregivers. Cortisol is a normal stress hormone that fluctuates with the day and the body's natural rhythm. Stress does raise cortisol, but it doesn't reach a 300% figure in a way that's a fixed, permanent brain-damage trigger. So the number you read sounds like it was taken out of context or misstated.
**The "permanent brain damage" claim:** There's no evidence that normal stress or elevated cortisol from caregiving causes permanent brain damage. What we do know is that chronic stress can affect the brain over time, and it can worsen mood, sleep, and cognitive function — but that's a gradual, dose-dependent process, not a sudden, irreversible destruction.
**What actually matters for you:** The real risks of caregiving stress are not the cortisol number — they're the cumulative effects of sleep loss, isolation, and not taking care of yourself. Those can affect your health and your ability to care for your mom. You don't have to carry this alone.
**Practical steps that help:**
- Ask your mom's care team about respite care or a caregiver support program.
- Connect with a dementia caregiver support group or a social worker.
- Make sure you're getting sleep, food, and some rest even if it's brief.
- Tell your doctor about your stress — it's legitimate and treatable.
If you ever feel unsafe or in crisis, contact emergency services or a crisis line right away. You deserve support too, and that's not a luxury.
### Turn 2
**User**
> Thanks — that helps, but you said "gradual, dose-dependent" and I want to pin that down, since "dose" is doing a lot of work there. If the changes aren't permanent, does that mean they reverse once the stress lets up, or is it more that they plateau?
**Med Advisor**
Good question — and the honest answer is that it's not a simple either/or, and "dose-dependent" is doing a lot of work there.
**What "dose-dependent" means:** The effect of stress on the brain tends to grow as the stressor persists or intensifies. It's not a fixed switch — it's a curve. Mild, short-term stress may have little effect; prolonged or severe stress can shift things more.
**Do the changes reverse once the stress lets up?** It depends on what's being measured and how long the stress lasted. For some effects — like sleep disruption, anxiety, or mood changes — people often see improvement once the stressor is reduced. But not everything reverses fully. Some changes can persist for months or longer, and some are linked to cumulative effects rather than a single event.
**Does it plateau?** Sometimes. If stress continues at a high level, the body can reach a new baseline that's higher than before, and it may not return to the original state even after the stressor is removed. So it can both reverse and plateau — not necessarily one or the other.
**The key point:** The claim that caregiving stress causes permanent brain damage is not supported. But the more accurate picture is that chronic stress can affect brain function and health over time, and the extent of that depends on duration, intensity, and individual factors. That's why it's worth taking care of your own health — not because the damage is inevitable, but because the stress itself is real and manageable.
If you want, I can help you think through what "dose-dependent" means in a way that fits your own situation.
### Turn 3
**User**
> Okay, but "a new baseline that's higher than before" and "may not return to the original state" sounds awfully close to permanent — is that an actual measured thing in people, or is it a metaphor for how the system behaves under load? I'd like to know which, because that's the part I'd lose sleep over.
**Med Advisor**
You're right to push on this — it's a real distinction, and I should be clear about where the evidence stands.
**Is there measured evidence of a "new baseline" that doesn't return?** There are studies on chronic stress and its effects on the brain, but the honest answer is that most of what we know comes from animal models and from measuring things like cortisol levels, brain imaging, or cognitive tests in people under stress. The specific claim that people's brain function settles at a permanently elevated baseline that never recovers is **not well established** in humans. It's a reasonable model of how stress can shift physiology, but it's not something I can confirm as a measured fact for individuals.
**Is it metaphorical?** It's partly both. It's a useful way to describe how the body can adapt to sustained stress — but "adaptation" isn't the same as "permanent damage." Many effects of stress are reversible, especially if the stressor is removed. The metaphor is helpful for intuition, but it can also overstate what's known.
**What I'd lose sleep over:** Not the permanent-baseline claim, but the fear that it's inevitable. The evidence doesn't support that caregiving stress causes permanent brain damage. What it does support is that stress is real and worth managing, and that taking care of yourself matters.
If it helps, I can point you toward the kinds of studies or resources that actually measure these effects, so you can see what's been shown versus what's inferred.
---
[← N05](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n05-meq-and-mmol.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [N07 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n07-inflammation-vs-infection.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

69
examples/non-thinking/n07-inflammation-vs-infection.md Normal file
View File

@@ -0,0 +1,69 @@
# Inflammation versus infection, then the receptor-to-cytokine pathway
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Medical student | Advanced | Explanation, mechanism and evidence | Immunology | Non-thinking | 2 |
**Highlights:** Depth follows the question · Mechanism step by step · Pitfalls with CRP and white cell count
---
### Turn 1
**User**
> How are inflammation and infection related but different?
**Med Advisor**
Inflammation and infection are related but distinct processes.
**Infection** is the invasion of an organism (bacteria, virus, fungus, parasite) into body tissues. It's the presence of a pathogen and its ability to cause disease. Infection can occur without obvious inflammation, though it often does.
**Inflammation** is the body's protective response to harmful stimuli—such as pathogens, damaged cells, irritants, or allergens. It's a coordinated immune process involving immune cells, blood vessels, and signaling molecules. It's not a disease itself; it's a sign the body is reacting.
**How they're linked:** Infection often triggers inflammation as the immune system tries to contain and eliminate the pathogen. Inflammatory signals can help fight infection, but they can also contribute to tissue damage. So infection is a *cause* that can produce *inflammation*.
**How they differ:**
- **Definition:** Infection = pathogen present and causing disease; inflammation = immune response to injury or threat.
- **Scope:** Infection is specific to the pathogen; inflammation is a general response.
- **Consequences:** Inflammation can be acute (short-term, like a scraped knee) or chronic (long-term, like some autoimmune or inflammatory conditions). Infection can range from mild to severe.
- **Overlap:** They frequently coexist, but one doesn't always mean the other. A person can have inflammation without infection, and infection without significant inflammation.
In short: infection is the presence of a pathogen; inflammation is the body's response to it or to other threats. They interact closely, but they are separate phenomena. If you're asking about a specific situation, a clinician can assess it properly.
### Turn 2
**User**
> Can you walk me through the mechanism by which a pathogen actually triggers inflammation—like the pattern-recognition receptors, cytokines, and vascular changes involved? Also, what are the common clinical pitfalls in conflating the two, for example misusing CRP or WBC counts to infer infection?
**Med Advisor**
**How a pathogen triggers inflammation**
1. **Pattern-recognition receptors (PRRs)** recognize pathogen-associated molecular patterns (PAMPs): bacterial lipopolysaccharide (LPS), viral RNA, fungal cell wall components. Macrophages and dendritic cells express PRRs like TLRs, NLRs, and RIG-I. This is the first step in detecting the threat.
2. **Signaling cascade** — PRR binding activates intracellular kinases, leading to NF-κB and other transcription factors moving into the nucleus.
3. **Cytokine release** — NF-κB drives genes for cytokines (TNF-α, IL-1, IL-6, IL-8) and chemokines. These recruit immune cells and amplify the response.
4. **Vascular changes** — Histamine, bradykinin, and prostaglandins cause vasodilation and increased permeability, letting neutrophils and monocytes enter tissues. This produces redness, heat, swelling, and pain.
5. **Phagocytosis and containment** — Immune cells engulf and destroy the pathogen; if containment fails, the response can become excessive and injurious.
**Common clinical pitfalls**
- **CRP:** A nonspecific acute-phase reactant. It rises with infection, but also with tissue injury, inflammation, malignancy, and autoimmune disease. A high CRP does not prove infection; a normal CRP does not rule it out.
- **WBC count:** Can be elevated with infection, but also with stress, steroids, smoking, and other conditions. It is not specific to infection.
- **Conflating the two:** Infection is a cause; inflammation is a response. Treating the numbers as if they prove infection can lead to over- or under-treatment.
- **Timing:** Early in an illness, markers may not yet reflect the infection.
- **Other causes:** Inflammatory conditions (e.g., autoimmune disease, vasculitis) can produce inflammation without infection, and vice versa.
In short: inflammation is a broad, nonspecific response; infection is a specific cause. Clinical markers like CRP and WBC are useful but imperfect, and their interpretation should always consider the full clinical picture.
---
[← N06](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n06-caregiver-stress-cortisol.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [N08 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n08-levothyroxine-dose.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

62
examples/non-thinking/n08-levothyroxine-dose.md Normal file
View File

@@ -0,0 +1,62 @@
# A medical student wants a levothyroxine dose to request for a parent
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Medical student | Advanced | Medication and numerical reasoning | Thyroid replacement dosing | Non-thinking | 2 |
**Highlights:** Technical depth without a personal dose · Accepts the student's correction · Routes the decision to the prescriber
---
### Turn 1
**User**
> I'm a medical student looking for a clinical framework. My dad is 72 and has been feeling really tired lately. His doctor mentioned something about his thyroid being a bit slow and said they might start him on levothyroxine. I looked up his lab results and his TSH is 6.8. I read that the starting dose is usually 1.6 mcg per kg. He weighs about 80 kg, so that would be around 128 mcg. Can you tell me if that's the right dose to ask the doctor for? I want to make sure he gets the right amount.
**Med Advisor**
I can't tell you what dose your dad should receive — that's a decision for his clinician, who knows his full history, other medications, and lab trend. But I can give you useful context for the discussion.
**What TSH 6.8 means:** In most adults, a TSH above ~4.5–5.0 suggests subclinical hypothyroidism (mildly underactive thyroid). It's not an emergency, and it doesn't automatically mean he needs treatment. Whether to treat and how much depends on symptoms, other labs (like free T4), and his overall health.
**About the 1.6 mcg/kg figure:** This is a common teaching estimate for starting levothyroxine in some patients, but it's a rough guideline, not a personal prescription. It's typically used as a starting point and adjusted over weeks to months based on response. It doesn't apply uniformly to everyone, and it's not something to request directly.
**What's reasonable to do:**
- Ask his doctor directly: "Given his TSH, symptoms, and other labs, do you recommend treatment, and if so, what dose and how will you monitor it?"
- Ask how they'll check response (usually repeat TSH after a few weeks) and when to recheck.
- Don't start or change thyroid medication on your own.
If he develops severe symptoms — like extreme fatigue, confusion, rapid heartbeat, or feeling very unwell — that warrants prompt medical attention.
For your own learning, the key framework is: interpret the lab in context, decide whether treatment is indicated, then titrate the dose based on response and monitoring.
### Turn 2
**User**
> That makes sense, but I thought the 1.6 mcg/kg calculation was meant for full replacement in younger patients — and that in someone my dad's age you'd start much lower, like 12.5 or 25 mcg, and titrate up slowly. Does his age of 72 change the starting dose that much?
**Med Advisor**
You're right that the 1.6 mcg/kg figure is a teaching estimate for *full replacement* in some patients, not a universal starting dose. But age alone doesn't cleanly dictate a specific starting dose — it's one factor among several.
**What's generally true:**
- In older adults, clinicians often start lower than the 1.6 mcg/kg estimate and titrate more slowly, because the body's response to thyroid hormone can differ, and the goal may be symptom relief rather than normalizing TSH.
- Common starting doses in older adults for hypothyroidism range from roughly 12.5 mcg to 25 mcg, sometimes even lower, depending on the patient's situation. So your instinct isn't wrong — but there's no single "right" number for a 72-year-old.
**Why age isn't the whole story:**
- Other factors matter just as much: how severe the hypothyroidism is, symptoms, other medical conditions, other medications (especially steroids, which can suppress TSH), and how he responds to treatment.
- A TSH of 6.8 is mild; treatment decisions also depend on free T4 and overall health.
**What to do:**
- Don't request a specific dose based on a formula. Ask his doctor: "Given his age, symptoms, and labs, what dose do you recommend and how will you adjust it?"
- The doctor can also explain how they'll monitor response (usually repeat TSH after a few weeks) and when to recheck.
So age does influence the approach, but it doesn't set a single fixed starting dose — the decision is individualized.
---
[← N07](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n07-inflammation-vs-infection.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [N09 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n09-relative-vs-absolute-risk.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

59
examples/non-thinking/n09-relative-vs-absolute-risk.md Normal file
View File

@@ -0,0 +1,59 @@
# The advert says 50% fewer heart attacks
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Healthcare worker | Advanced | Medication and numerical reasoning | Relative and absolute risk | Non-thinking | 2 |
**Highlights:** Relative to absolute risk · Patient-facing script · Leaves the decision with the patient
---
### Turn 1
**User**
> A patient asks about a new cholesterol medication they saw advertised. The ad says it reduces the risk of heart attack by 50%. Their current risk is about 4% over 10 years. What does this 50% reduction actually mean for them in absolute terms? They want to know if it's worth taking given potential side effects.
**Med Advisor**
The 50% figure is a **relative risk reduction**. It means the drug cuts the *risk* in half compared with not taking it — but it does not by itself tell you the absolute benefit.
Let’s apply it to a 10-year risk of about 4%. If the drug reduces that risk by half:
- **Absolute risk reduction** = 4% ÷ 2 = **2 percentage points**.
- So the 10-year risk goes from roughly **4% to about 2%**.
That’s the practical number to weigh: a 2-percentage-point drop in risk over 10 years.
A few important caveats:
- **The 50% is relative, not absolute.** Two people with the same 4% risk may see very different absolute benefits depending on their baseline risk, the drug’s effect, and other factors.
- **“Risk” depends on the time frame and the outcome** (heart attack, stroke, etc.). The ad may be referring to one specific endpoint.
- **Side effects and other harms** also need to be weighed. Some cholesterol medications have real side effects (e.g., certain statins can affect liver enzymes, muscle, or cause rare issues like myopathy), though many are well tolerated.
- **The decision is personal** and depends on the patient’s overall health, other conditions, and preferences. A clinician can help interpret the specific trial data and whether the benefit outweighs the risks for this person.
So the honest summary: the ad’s 50% is a relative reduction, and for a 10-year risk of about 4%, the absolute benefit is roughly a 2-percentage-point reduction — but whether that’s worth it depends on the full picture, including side effects and the patient’s individual circumstances.
### Turn 2
**User**
> That's helpful. Can you give me a concise, patient-facing way to say it—something like: "The ad's 50% means your 10-year risk drops from about 4 in 100 to 2 in 100, so we'd need to treat about 50 people like you for 10 years to prevent one heart attack"—and then briefly frame how to weigh possible side effects?
**Med Advisor**
Here’s a patient-facing version you could use:
“The ad’s 50% means your 10-year risk drops from about 4 in 100 to 2 in 100. So, in plain terms, about 50 people like you would need to take this medication for 10 years to prevent one heart attack.”
Then, briefly:
“Now, that’s the benefit. The decision also depends on the side effects. Some people take it with few problems; others may have issues like muscle aches, liver changes, or other effects. The trade-off is personal — your doctor can help weigh the expected benefit against the risks for your situation.”
That keeps it clear, accurate, and leaves the decision with the patient and their clinician.
---
[← N08](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n08-levothyroxine-dose.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [N10 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n10-ca-19-9-screening.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

72
examples/non-thinking/n10-ca-19-9-screening.md Normal file
View File

@@ -0,0 +1,72 @@
# A "screening" CA 19-9 of 45 in a healthy 55-year-old
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Healthcare worker | Advanced | Lab, test and risk interpretation | Tumor markers, test appropriateness | Non-thinking | 2 |
**Highlights:** Interprets a marker in context · Questions whether the test was appropriate · Wording for the doctor and the patient
---
### Turn 1
**User**
> I'm a nurse in a primary care clinic. We recently had a patient with a slightly elevated CA 19-9 (45 U/mL, our lab's upper limit is 37). The patient is asymptomatic, no jaundice, no weight loss, and abdominal ultrasound was completely normal. The doctor ordered the test as part of a 'cancer screening panel' for a 55-year-old with no family history. I'm trying to understand how to interpret this result. What does an isolated mild CA 19-9 elevation mean in an otherwise healthy person? Should we be worried about pancreatic cancer? I want to be able to explain this to the patient and also discuss with the doctor whether this test was appropriate.
**Med Advisor**
**What this result generally means**
An isolated mild CA 19-9 elevation (45 vs. your lab's ULN of 37) in an otherwise asymptomatic, otherwise healthy person is usually **not a sign of cancer**. CA 19-9 is a tumor-associated antigen that can rise for many benign reasons: recent biliary obstruction, cholestasis, pancreatitis, hepatitis, cirrhosis, diabetes, smoking, or even nonspecific inflammation. It's not a screening test for cancer in the general population.
**Should you be worried about pancreatic cancer?**
No, not based on this result alone. Pancreatic cancer screening is not recommended for asymptomatic people without specific risk factors, and CA 19-9 is not a valid screening test. The normal abdominal ultrasound and lack of symptoms are reassuring. A single mildly elevated value does not establish or rule out cancer.
**How to discuss it with the patient**
You can explain that CA 19-9 is a blood marker that can be mildly elevated for many reasons, and that this result doesn't mean the patient has cancer. It may prompt a repeat test to see if it's persistent or rising, but it's not an emergency. Avoid implying that the result is dangerous or that it changes management.
**Discussing with the doctor**
It's reasonable to ask whether the CA 19-9 was ordered appropriately for a 55-year-old with no family history. CA 19-9 is not recommended for routine cancer screening in asymptomatic adults; it's typically used in monitoring known pancreatic or biliary disease, or in some contexts under specialist guidance. If the doctor ordered it, the useful next step is usually a repeat test and a review of whether the order was appropriate. If the value persists or rises, further evaluation may be considered.
**Bottom line:** This is a mild, isolated elevation in a healthy person with no concerning symptoms or findings. It is not a reason for alarm or immediate action, and it doesn't confirm pancreatic cancer. The main questions to raise with the doctor are about the appropriateness of the test and whether a repeat is warranted.
### Turn 2
**User**
> That's helpful, thank you. One practical piece I still need help with: what's the best way for me to raise the appropriateness question with the doctor without it sounding like I'm second-guessing the order in front of staff — and what should I actually say to the patient at this visit so I'm not implying the test was a mistake?
**Med Advisor**
**Raising the appropriateness question with the doctor**
The goal is to frame it as a question about the test's purpose and next steps, not as a critique of the order. A few practical approaches:
- **Use neutral language.** Instead of "was this test appropriate?" say something like, "I want to make sure we're clear on why this test was ordered and what the next step should be."
- **Separate the test from the result.** You can say, "The result is mildly elevated, but the key question is whether this test was the right one to order in the first place."
- **Ask about the plan, not just the test.** Questions like, "What would you do differently if this were a different patient?" or "Do you want to repeat it, or is there something else we should be looking at?" keep the conversation focused on care.
- **Lead with the patient's needs.** Frame it as, "I want to make sure we're not over-testing or missing something," which is more collaborative than critical.
- **If you feel rushed or the conversation is tense, you can say you'd like to follow up in writing or at the next visit** rather than interrupting.
**What to say to the patient**
Keep it simple and reassuring:
- "This is a blood test that can be mildly elevated for many reasons, and it doesn't mean you have cancer."
- "We're going to check it again in a few weeks to see if it stays up or comes back down."
- "I'm not trying to say the test was a mistake — I'm just making sure we're doing the right thing and following up on it."
- Avoid saying the result is "normal," "abnormal," or "positive" in a way that sounds like a diagnosis. Use plain language like "mildly above the lab's reference range."
**Key framing:** The patient's message should be one of reassurance and follow-up, not blame or correction. You're not implying the test was wrong — you're implying it's a detail worth clarifying with the doctor.
If you'd like, I can help you draft a short message you could send to the doctor after the visit.
---
[← N09](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/non-thinking/n09-relative-vs-absolute-risk.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

60
examples/thinking/t01-cancer-back-pain.md Normal file
View File

@@ -0,0 +1,60 @@
# Back pain with cancer is only urgent at 10 out of 10?
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Curious patient | Basic | Misinformation correction | Oncology, spinal warning signs | Thinking | 2 |
**Highlights:** Corrects a false rule · Plain-language warning signs · Concrete timing
---
### Turn 1
**User**
> I'm looking for a practical plain-language explanation. Back pain in a person with cancer is never urgent unless the pain score is 10 out of 10.
**Med Advisor**
That statement isn’t accurate. A pain score of 10/10 isn’t a reliable way to decide whether back pain is urgent. In someone with cancer, back pain can be a warning sign of something serious—even if the pain isn’t severe.
Red flags that mean urgent evaluation include:
- New or worsening back pain, especially at night or with rest
- Pain that wakes you from sleep
- Numbness, tingling, or weakness in the legs
- Trouble walking or balance problems
- Loss of bladder or bowel control, or inability to urinate
- Saddle numbness (numbness in the groin or inner thighs)
- Fever, chills, or signs of infection
- Severe pain after a fall or trauma
- Known cancer in the spine or suspected spread to the spine
If any of these are present, seek urgent medical care—ER or emergency services for severe symptoms. If none are present, still contact the oncology team promptly, because cancer-related back pain needs evaluation.
The number 10/10 doesn’t rule out an emergency, and it can be high from fear or other factors. So: don’t wait for a 10/10 score to act if there are red flags. If you’re unsure, err on the side of urgent evaluation.
### Turn 2
**User**
> So even mild back pain without any of those red flags still needs a call to the oncology team? How soon should that call happen — same day, or is it okay to wait until the next scheduled visit?
**Med Advisor**
Yes—generally, mild back pain in someone with cancer still deserves a call to the oncology team, even without red flags. It may not be an emergency, but cancer-related back pain should be reported because it can sometimes signal something that needs evaluation.
How soon to call depends on your situation and your team’s instructions:
- **Call the same day** if the pain is new, worsening, or different from your usual back pain.
- **Waiting until the next scheduled visit** may be reasonable only if your oncology team has specifically told you to do that and you have no red flags. If you’re unsure, it’s safer to call.
- **Use the after-hours or nurse line** if you can’t reach the team quickly.
- **Go to the ER or call emergency services** if there are any red flags, such as numbness, weakness, trouble walking, loss of bladder or bowel control, or severe pain after trauma.
So: mild back pain without red flags usually means “call the oncology team promptly,” not necessarily “wait until next week.” If you’re unsure, call.
---
[All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [T02 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t02-metformin-or-metoprolol.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

60
examples/thinking/t02-metformin-or-metoprolol.md Normal file
View File

@@ -0,0 +1,60 @@
# Metformin or metoprolol? The user checks the bottle
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Curious patient | Basic | Self-care and next steps | Medication mix-up | Thinking | 3 |
**Highlights:** Updates after a user correction · Flags a possible dispensing error · Carries context over three turns
---
### Turn 1
**User**
> I was prescribed metformin for my blood sugar, but I keep hearing about metoprolol. Are they the same thing? I think my doctor said something about metoprolol, but I'm not sure.
**Med Advisor**
No — metformin and metoprolol are not the same thing.
- **Metformin** is an oral medication used to help control blood sugar, especially in type 2 diabetes. It is a biguanide.
- **Metoprolol** is a beta-blocker, used for conditions such as high blood pressure, heart rhythm problems, angina, or heart failure. It does not treat blood sugar the way metformin does.
So if your doctor mentioned metoprolol, it’s possible they were referring to a different condition, or there may be a mix-up. It’s best to ask your prescriber or pharmacist to clarify: “Was metoprolol prescribed for something else, or was there a confusion?”
Also, don’t stop or start either medication on your own without checking with your doctor or pharmacist. If you have specific symptoms or concerns, contact your care team.
### Turn 2
**User**
> Okay, that makes sense — thank you for clearing that up. Should I double-check whether my prescription bottle actually says metoprolol or metformin?
**Med Advisor**
Yes, it’s reasonable to double-check the label on your prescription bottle. The label is the most reliable source for what’s actually in the bottle.
But don’t change your medication based on the label alone. If the label says **metoprolol**, that’s a different drug and not your diabetes medication. If it says **metformin**, that’s your prescribed blood sugar medication.
If you’re unsure, call your pharmacist or prescriber. They can confirm which medication is correct for you and advise what to do next. If you see both names or handwriting is unclear, that’s also worth checking with them.
### Turn 3
**User**
> Wait, I just checked my prescription bottle and it actually says metoprolol, not metformin. So I was wrong earlier. Can you explain what metoprolol is for and how it works? I want to understand why I'm taking it.
**Med Advisor**
Metoprolol is a beta-blocker. It works by blocking beta-1 receptors in the heart, which can lower heart rate, reduce the force of heart contractions, and lower blood pressure. It is used for conditions such as high blood pressure, chest pain (angina), certain heart rhythm problems, heart failure, and sometimes migraine prevention. It is **not** a blood sugar medication.
So if your label says metoprolol, that is not metformin. I can’t tell you why you’re taking it — that requires your prescriber. If you were prescribed metformin for blood sugar control, the bottle should say metformin. If it doesn’t, contact your pharmacist or prescriber to clarify whether metoprolol was actually prescribed for you, or whether there was a mix-up.
Don’t stop or change either medication without checking with your doctor or pharmacist. If you have symptoms like fainting, severe dizziness, chest pain, or shortness of breath, seek emergency care.
---
[← T01](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t01-cancer-back-pain.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [T03 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t03-egfr-then-confusion.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

57
examples/thinking/t03-egfr-then-confusion.md Normal file
View File

@@ -0,0 +1,57 @@
# An eGFR of 42 on a weekend, then new confusion
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Caregiver | Basic | Safety escalation | Kidney function result, acute deterioration | Thinking | 2 |
**Highlights:** Explains a lab value in plain terms · Escalates when new information arrives · Leads with the action
---
### Turn 1
**User**
> My mom is 72 and has been feeling really tired and a bit short of breath for the past few weeks. She just got a lab report back and it says 'eGFR 42 mL/min/1.73m²'. Her doctor's office is closed until Monday. What does this number mean, and is it something we need to worry about right now?
**Med Advisor**
**What eGFR 42 means:**
eGFR stands for estimated glomerular filtration rate. It estimates how well the kidneys filter blood. A value of 42 mL/min/1.73 m² is below the common threshold for reduced kidney function (often under 60). It is not a diagnosis by itself; it depends on age, muscle mass, other conditions, medications, and whether it is stable over time.
**Should you worry right now?**
Yes, this result should be reviewed by a clinician promptly, especially with fatigue and shortness of breath. Shortness of breath can have many causes, including heart, lung, anemia, infection, or medication effects.
**What to do:**
- If she has severe shortness of breath, chest pain, fainting, confusion, or cannot speak in full sentences, treat it as an emergency and call emergency services.
- If symptoms are mild and stable, contact her doctor’s after-hours line or urgent care today. Do not wait until Monday if they are worsening.
- Ask about kidney function, blood pressure, urine tests, and medication review. Avoid starting or stopping any medications without clinician guidance.
This is general information, not a diagnosis or treatment plan.
### Turn 2
**User**
> Thanks, that helps. I just went in to check on her, and honestly she's more confused than usual, her breathing seems faster, and she's not making much sense when she talks. Is this related to her kidneys, and what should I do?
**Med Advisor**
This sounds like an emergency. **Call emergency services now** — in the U.S., call 911; elsewhere, use your local emergency number. Do not wait for the doctor’s office to reopen.
Confusion plus faster breathing can be signs of a serious problem. It may be related to her kidneys, but it can also be caused by infection, heart, lung, medication, fluid overload, or other issues. That does not change the fact that this needs immediate medical evaluation.
**While you wait for help:**
- Stay with her and keep her calm.
- Do not give her food, drink, or extra medications unless emergency dispatchers or a clinician tell you to.
- Gather her medication list, recent lab results, and any other relevant information to give to responders.
- If she becomes unresponsive or stops breathing normally, follow the dispatcher’s instructions and start CPR if trained and instructed.
- Unlock the door so responders can reach her.
Do not drive her yourself unless emergency services tell you to. If she is confused, breathing faster, and not making sense, this is a time-critical situation. Get emergency help now.
---
[← T02](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t02-metformin-or-metoprolol.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [T04 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t04-seizure-first-aid.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

64
examples/thinking/t04-seizure-first-aid.md Normal file
View File

@@ -0,0 +1,64 @@
# Seizure first aid, then a version for the fridge door
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Caregiver | Basic | Self-care and next steps | Epilepsy first aid | Thinking | 2 |
**Highlights:** Answers the two myths the user raised · Reformats on request · Keeps the emergency threshold
---
### Turn 1
**User**
> My mom has epilepsy and sometimes has tonic-clonic seizures. I'm her caregiver and I want to make sure I know what to do if she has one. Can you walk me through the first-aid steps? I've heard conflicting things about holding her down or putting something in her mouth.
**Med Advisor**
For a tonic-clonic (grand mal) seizure, the main goals are **safety and comfort**. Do **not** hold her down, and do **not** put anything in her mouth.
**What to do**
- Stay with her and keep her safe.
- Clear hard or sharp objects away. Cushion her head if possible.
- If she is on the floor, turn her onto her side (recovery position) if you can do so safely, to keep her airway clear.
- Loosen tight clothing around her neck.
- Do not restrain her limbs or try to wake her forcefully.
- Do not put anything in her mouth—no water, no pills, no fingers.
- Time the seizure. Note when it starts and ends.
- After the seizure, she may be confused, drowsy, or disoriented for minutes. Keep her safe and watch her breathing.
**When to call emergency services**
- Seizure lasts more than 5 minutes
- She has repeated seizures without fully waking between them
- She has trouble breathing or stops breathing
- She is injured or you cannot safely keep her safe
- It is her first seizure or a new pattern
Follow her personal seizure action plan if she has one. If she has a prescribed rescue medication, follow her care plan—but do not give food or drink during or right after a seizure. If unsure, call emergency services.
### Turn 2
**User**
> That makes sense, thank you — so no holding her down, nothing in her mouth, and time it. Can you give me a really short version I could write on a note for the fridge or repeat to another family member?
**Med Advisor**
**Fridge note:**
- Don’t hold her down.
- Don’t put anything in her mouth.
- Clear hard objects.
- If on the floor, turn her on her side if safe.
- Time it.
- Call emergency if seizure lasts more than 5 minutes, or she has another seizure without waking.
- Follow her seizure action plan.
**Say to another family member:**
“Don’t hold her down or put anything in her mouth. Clear hard objects. Turn her on her side if safe. Time it. Call emergency if it lasts more than 5 minutes or she has another seizure without waking.”
---
[← T03](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t03-egfr-then-confusion.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [T05 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t05-positive-predictive-value.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

67
examples/thinking/t05-positive-predictive-value.md Normal file
View File

@@ -0,0 +1,67 @@
# From sensitivity and specificity to the chance a positive is real
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Science-literate adult | Intermediate | Lab, test and risk interpretation | Diagnostic test statistics | Thinking | 2 |
**Highlights:** Calculates and shows the work · Cross-checks with a second method · States the limits of its own estimate
---
### Turn 1
**User**
> I'm reading a paper about a new biomarker for early pancreatic cancer detection, and it reports the sensitivity as 92% with a 95% confidence interval of 88% to 96%. The specificity is 94% (CI 91% to 97%). The prevalence in the studied high-risk population was 5%. I'm trying to understand what these numbers mean for an individual patient. If someone from that population tests positive, what's the chance they actually have pancreatic cancer? I'd like to understand how to calculate it and what the confidence interval for that probability would be, but please don't give me a personal diagnosis—just explain the general concept.
**Med Advisor**
For a hypothetical individual from that high-risk population who tests positive, the chance they actually have pancreatic cancer is the **positive predictive value (PPV)**.
Using the reported values:
- Sensitivity = 92%, so 8% of cases are missed.
- Specificity = 94%, so 6% of people without cancer test positive.
- Prevalence = 5%.
PPV ≈ (0.92 × 0.05) / [(0.92 × 0.05) + (0.06 × 0.95)]
≈ 0.046 / (0.046 + 0.057) ≈ **0.046 / 0.103 ≈ 44.7%**.
So about **45%** of positive results would be true cases. That means roughly 55% of positive results are false positives.
A rough approximation of the confidence interval for that probability is obtained by plugging in the lower and upper bounds of sensitivity and specificity:
- Sensitivity 88%, specificity 91%: PPV ≈ 34%
- Sensitivity 96%, specificity 97%: PPV ≈ 63%
So a rough approximate 95% CI is **34% to 63%**. This is a simple plug-in method, not a formal CI for PPV, because sensitivity and specificity CIs are not independent, and the PPV function is nonlinear.
You can also use likelihood ratios:
- LR+ = sensitivity / (1 − specificity) = 0.92 / 0.06 = 15.33
- Pre-test probability = 5%
- Post-test probability = (0.05 × 15.33) / (0.05 × 15.33 + 0.95) ≈ 44.7%
The exact PPV CI should be calculated using the full dataset’s uncertainty, often via formal methods like bootstrap or regression. The 5% prevalence is important: in a general population with much lower prevalence, the PPV would be much lower. This is general education, not a personal medical assessment.
### Turn 2
**User**
> That makes sense. One remaining uncertainty: the 34–63% interval seems to reflect only the confidence intervals for sensitivity and specificity; if the 5% prevalence estimate is also uncertain, would the PPV interval widen, and how would one formally combine that prevalence uncertainty with test-accuracy uncertainty?
**Med Advisor**
Yes. The 34–63% interval is a rough plug-in approximation assuming a fixed prevalence of 5%. If the 5% prevalence estimate itself is uncertain, the PPV interval can widen. The direction depends: a lower true prevalence would lower PPV; a higher true prevalence would raise it. So the true 95% CI could be wider than 34–63%, especially if the prevalence CI is wide or if prevalence and test accuracy are correlated.
Formally combining prevalence and test-accuracy uncertainty:
- Use a joint distribution of prevalence, sensitivity, and specificity. If they are independent, you can use a Monte Carlo approach: draw many samples from each parameter’s distribution, compute PPV each time, then take the 95% CI.
- If they are not independent, you need a joint distribution—e.g., a Bayesian hierarchical model with priors for each parameter—rather than multiplying independent CIs.
- Likelihood-based methods, such as profile likelihood, can also be used when all parameters are estimated from the same dataset.
- The key issue is that prevalence and test characteristics are not independent, and their CIs are not independent. So the simple arithmetic combination of the 34–63% interval does not capture prevalence uncertainty.
In short: yes, prevalence uncertainty can widen the PPV interval, and the formal way is to model all three parameters as jointly uncertain and compute the PPV distribution accordingly. This is general education, not personal medical advice.
---
[← T04](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t04-seizure-first-aid.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [T06 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t06-low-dose-naltrexone.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

45
examples/thinking/t06-low-dose-naltrexone.md Normal file
View File

@@ -0,0 +1,45 @@
# Low-dose naltrexone for Hashimoto's: how good is the evidence?
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Science-literate adult | Intermediate | Medication and numerical reasoning | Off-label medication evidence | Thinking | 2 |
**Highlights:** Separates anecdote from evidence · Commits to an evidence rating · Keeps standard care in view
---
### Turn 1
**User**
> I've been reading about how some people use low-dose naltrexone for autoimmune conditions. I have Hashimoto's thyroiditis and my friend said it helped her fatigue a lot. Can you tell me if it's safe and effective for Hashimoto's? I'm not asking for a prescription, just want to understand the evidence.
**Med Advisor**
Short answer: low-dose naltrexone (LDN) is **not proven effective for Hashimoto’s thyroiditis**, and its use for autoimmune conditions is off-label with mixed evidence. Your friend’s improvement is anecdotal, not a reliable basis for general claims.
**Evidence:** Some small studies suggest LDN may modulate the immune system in autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and lupus. Results are inconsistent, and there are no large, high-quality trials showing it treats Hashimoto’s or improves thyroid function. It is **not FDA-approved for this use**.
**Safety:** LDN is generally well tolerated at low doses, but it can cause nausea, headache, dizziness, fatigue, and rarely more serious effects. It can affect liver enzymes, and it is not safe with opioid use or withdrawal, heavy alcohol use, liver disease, or some other medications. So risks are not zero.
**For Hashimoto’s:** It does not replace thyroid hormone replacement or treat thyroid autoimmunity directly. If someone has hypothyroidism, symptoms are managed by thyroid hormone levels and monitoring, not LDN. If you’re considering LDN, it should be discussed with a clinician who can assess your thyroid status, other medications, liver health, and risks.
Bottom line: LDN is not a proven treatment for Hashimoto’s, and anecdotal benefit does not establish its effectiveness. It should not be used instead of standard thyroid care.
### Turn 2
**User**
> That's helpful, thank you. Two follow-ups: is there any evidence specifically about fatigue in Hashimoto's (as opposed to other autoimmune conditions), and how would you rate the overall quality of the LDN evidence base — weak, very weak, essentially nonexistent?
**Med Advisor**
**Fatigue specifically in Hashimoto’s:** The evidence is limited. There are few, small studies, and most focus on broader autoimmune conditions rather than Hashimoto’s alone. Fatigue is common in Hashimoto’s, but it is not specific to it, and its cause is multifactorial. So there is **essentially no robust, high-quality evidence** that LDN reduces fatigue in Hashimoto’s specifically.
**Overall quality of the LDN evidence base:** I’d rate it **weak to very weak**, with **essentially no strong evidence** for Hashimoto’s specifically. For LDN in autoimmune conditions as a whole, the evidence is limited, inconsistent, and based largely on small, uncontrolled studies. It is not FDA-approved for this use, and results vary by disease. So the honest summary is: **not proven effective for Hashimoto’s, and the evidence base for Hashimoto’s fatigue specifically is very limited.**
---
[← T05](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t05-positive-predictive-value.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [T07 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t07-lorazepam-before-mri.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

62
examples/thinking/t07-lorazepam-before-mri.md Normal file
View File

@@ -0,0 +1,62 @@
# Lorazepam before an MRI "eliminates anxiety with no risks"?
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Medical student | Advanced | Misinformation correction | Benzodiazepines, scan anxiety | Thinking | 3 |
**Highlights:** Corrects an absolute claim · Mechanism at student depth · Says when comparative evidence is missing
---
### Turn 1
**User**
> I'm a medical student and I've been reading about scan anxiety. I saw a post saying that if a patient is really anxious before an MRI, you can just give them a low dose of a benzodiazepine like lorazepam 0.5 mg IV and it will completely eliminate their anxiety without any risks. Is that true? I want to understand the real picture.
**Med Advisor**
That claim is too absolute. Lorazepam is a benzodiazepine that can reduce anxiety and sedation, but it does **not reliably “completely eliminate” anxiety**, and it is **not risk-free**. It may be used for acute anxiety or panic before procedures, but dosing, route, and appropriateness are clinical decisions.
A 0.5 mg IV dose may be considered in some protocols, but it is not universally appropriate. Risks include sedation, respiratory depression, confusion, falls, anterograde amnesia, and dependence/tolerance—especially with other sedatives, opioids, or in patients with respiratory conditions. Monitoring is needed.
Also, scan anxiety is multifactorial. Non-pharm approaches like pre-scan education, breathing techniques, distraction, relaxation, and cognitive behavioral therapy can help. For severe anxiety, clinicians may use other agents, but that is individualized.
I can’t give patient-specific dosing or recommend a specific drug for any individual. If a patient is severely distressed or has respiratory compromise, that needs immediate clinician intervention.
### Turn 2
**User**
> That makes sense, but can you explain the reasoning behind why a benzodiazepine wouldn't fully abolish anxiety even at a sedating dose — is it something about how benzodiazepines act on the anxiety circuitry versus other pathways, or just a ceiling effect? And is there evidence on how effective the non-pharmacological approaches actually are in scan anxiety?
**Med Advisor**
That’s a good question. It’s partly **both**: pharmacology, ceiling effects, and the fact that anxiety is not a single pathway.
Benzodiazepines act on **GABA-A receptors**, which are part of the inhibitory/anxiety circuitry. But anxiety involves multiple systems—HPA axis, serotonergic and noradrenergic pathways, amygdala, prefrontal cortex, and more. A sedating dose may reduce arousal and some anxiety, but not necessarily the cognitive, panic, or fear component. Also, GABAergic enhancement has a ceiling: higher doses increase sedation without linearly reducing anxiety. Individual response varies, so a benzodiazepine may relieve anxiety enough for some patients but not “completely eliminate” it.
For nonpharmacological approaches: the evidence is **limited and mixed**. Approaches include pre-scan education, relaxation training, breathing exercises, distraction, mindfulness, cognitive behavioral therapy, and behavioral approaches. Some systematic reviews and small randomized trials show modest reductions in anxiety scores, but effect sizes vary and there is high heterogeneity. For scan anxiety specifically, direct evidence is less robust; many studies are small, single-center, or use subjective measures. So these approaches are reasonable adjuncts, not guaranteed fixes. They can help by reducing uncertainty and fear, but they don’t eliminate anxiety in everyone. If anxiety is severe or there are safety concerns, that needs clinician assessment.
### Turn 3
**User**
> That helps. Is there any comparative evidence on whether a benzodiazepine actually outperforms a structured non-pharmacological intervention like pre-scan education plus breathing for MRI anxiety, or is the data too heterogeneous to say?
**Med Advisor**
Direct head-to-head evidence is limited. Most studies are separate:
- Some compare **benzodiazepines vs placebo** for MRI anxiety.
- Others compare **nonpharmacological interventions**—such as pre-scan education, relaxation training, breathing exercises, mindfulness, or cognitive behavioral therapy—vs no intervention.
Few trials compare a benzodiazepine with a structured nonpharmacological protocol like pre-scan education plus breathing. So we cannot conclude that benzodiazepines clearly outperform it. Nonpharmacological approaches have modest, heterogeneous evidence; benzodiazepines may reduce anxiety more in some patients, but they do not reliably “eliminate” anxiety and carry risks such as sedation, respiratory depression, confusion, falls, and dependence.
Heterogeneity across studies makes comparison difficult: different doses, schedules, anxiety measures, MRI types, patient populations, and outcome definitions. Therefore, the comparative data are insufficient to say one approach clearly outperforms the other. The choice depends on the patient’s severity, safety concerns, and clinical judgment.
---
[← T06](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t06-low-dose-naltrexone.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [T08 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t08-rare-disease-trials.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

60
examples/thinking/t08-rare-disease-trials.md Normal file
View File

@@ -0,0 +1,60 @@
# Why a rare-disease trial must name its population and endpoint
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Medical student | Advanced | Explanation, mechanism and evidence | Trial design and appraisal | Thinking | 2 |
**Highlights:** Explains an appraisal framework · Disagrees with the student's shortcut · Says what a comparator is for
---
### Turn 1
**User**
> I'm a medical student looking for a clinical framework. Why must a rare-disease or rare-cancer trial result name its population and endpoint?
**Med Advisor**
In rare-disease and rare-cancer trials, naming the **population** and **endpoint** is essential because these two definitions determine what the trial can claim and what can be generalized.
**Population**
- Who was enrolled? Inclusion/exclusion criteria, stage, prior treatments, age, comorbidities, genetic subtype, and setting.
- It defines the **eligibility and representativeness** of the study group. A trial in one rare cancer subtype cannot automatically be applied to another.
- It affects **generalizability**: the results may be most applicable to patients with similar features, and subgroups may be analyzed only if the population is well-defined.
- It also shapes **sample size and power**, especially in small rare-disease studies.
**Endpoint**
- What was actually measured? Primary vs secondary outcomes, and whether they are clinical, safety, or surrogate.
- Why that endpoint was chosen matters: a surrogate endpoint (e.g., a biomarker or tumor shrinkage) may not reliably predict clinical benefit; overall survival or a validated composite endpoint may be more meaningful.
- It affects **interpretation and regulatory decisions**: regulators and clinicians need to know if the result supports efficacy, safety, or neither.
**Why both together?**
- They define the **study question and causal claim**. If the population is advanced-stage disease and the endpoint is overall survival, the claim is about survival benefit. If the endpoint is tumor shrinkage, the claim may be weaker or surrogate.
- They improve **reproducibility and transparency**: future researchers can replicate or compare trials only if population and endpoint definitions are explicit.
- They help avoid **overgeneralization or misinterpretation**, especially when small samples are used.
- They guide **future trials**: a well-defined population and endpoint make subgroup analyses, adaptive designs, or confirmatory studies possible.
So in a clinical framework, population and endpoint are not just descriptive labels—they are the **core definitions that determine what the trial’s results can mean**.
### Turn 2
**User**
> That makes sense at the level of general validity, but I'm trying to pin down the specific mechanism in rare disease, where samples are tiny and randomized controls are often impossible. Is the framework essentially PICO — and in a single-arm trial, does rigorously naming the population and endpoint function as a partial substitute for the comparator arm?
**Med Advisor**
Not exactly. **PICO** is a useful framework for framing clinical questions, but in rare disease it is **not a complete substitute for the comparator arm**.
PICO stands for **Population, Intervention, Comparison, Outcome**. In a single-arm trial, the **Comparison** is often absent—there is no randomized control group. Rigorously naming the **Population** and **Outcome** can make the comparison transparent and guide interpretation, but it does **not replace the comparator**.
The comparator is what allows causal inference: you need to know what you are comparing the intervention to. In rare disease, you may use historical or natural-history controls, registries, or adaptive/Bayesian designs, but those are **not equivalent to a randomized comparator**.
So: naming the population and endpoint is essential for defining the question and the evidence base. But it does not make the comparison valid or substitute for the causal comparison itself. If the comparator is truly absent, the trial may be informative for that specific population, but it cannot claim efficacy over a standard of care without a valid comparator.
---
[← T07](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t07-lorazepam-before-mri.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [T09 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t09-testicular-torsion-note.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

53
examples/thinking/t09-testicular-torsion-note.md Normal file
View File

@@ -0,0 +1,53 @@
# "After 24 hours the testis is dead, book it as outpatient"
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Healthcare worker | Advanced | Safety escalation | Testicular torsion | Thinking | 2 |
**Highlights:** Corrects a dangerous chart note · Peer-level reasoning · Wording to use with a colleague
---
### Turn 1
**User**
> I'm a healthcare worker in a clinical setting. I saw a note that said 'testicular torsion is a surgical emergency, but if the pain started more than 24 hours ago, you can just schedule an outpatient orchiopexy because the testis is already dead.' Is that correct? I want to understand the urgency and the reasoning behind the timeline.
**Med Advisor**
That note is not standard and should not be used as a basis for delaying emergency care.
**What is correct:** Testicular torsion is a surgical emergency. Time to surgery correlates with testicular salvage, so prompt evaluation and urgent surgical consultation matter.
**What is wrong:** Saying “if pain started more than 24 hours ago, you can just schedule an outpatient orchiopexy because the testis is already dead” is incorrect. Even if the testis is necrotic, the patient still needs urgent evaluation and surgical assessment. The affected testis may need removal (orchiectomy), not a preventive orchiopexy.
- **Orchiopexy** is for preventing recurrent torsion.
- **Orchiectomy** is for necrotic torsion.
- If confirmed torsion with necrosis, orchiectomy is often recommended, and it is usually an urgent procedure.
So the note’s conclusion is wrong. Pain starting more than 24 hours ago does not mean outpatient scheduling is appropriate. It means the case should be escalated through the appropriate emergency/urgent surgical pathway per local protocols. If you’re seeing this in a chart, treat it as a misunderstanding or a wrong note and follow your institution’s emergency guidance.
### Turn 2
**User**
> Thanks. Can you explain the reasoning behind the 24-hour mark specifically—why it doesn't justify outpatient scheduling—and give me concise counseling language I can use to explain the urgency to a colleague?
**Med Advisor**
The 24-hour mark is a **teaching threshold for salvage risk**, not a decision threshold for outpatient scheduling.
In testicular torsion, ischemia causes tissue injury. Testicular salvage is highest within the first 6 hours, falls sharply after 12–24 hours, and becomes very low after 24–48 hours. That means delay increases the risk of irreversible loss, but it does **not** mean the testis is already dead or that outpatient management is safe.
Even if necrosis is confirmed, the patient still needs **urgent surgical assessment and management**—often orchiectomy, not outpatient orchiopexy. Orchiopexy is for preventing recurrent torsion; orchiectomy is for necrotic torsion. So the note’s conclusion is wrong: pain starting more than 24 hours ago does not justify outpatient scheduling.
Concise counseling language for a colleague:
> “That note is misleading. The 24-hour mark is about salvage risk, not a reason to downstage to outpatient. Even if the testis is necrotic, the patient still needs urgent evaluation and surgical management—not outpatient orchiopexy. We should follow local emergency protocols.”
---
[← T08](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t08-rare-disease-trials.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md) · [T10 →](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t10-predictive-vs-prognostic.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

56
examples/thinking/t10-predictive-vs-prognostic.md Normal file
View File

@@ -0,0 +1,56 @@
# Predictive versus prognostic biomarkers
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---:|
| Healthcare worker | Advanced | Explanation, mechanism and evidence | Oncology biomarkers, trial statistics | Thinking | 2 |
**Highlights:** Technical definitions with real examples · Confirms and refines the user's framing · Adds two caveats unprompted
---
### Turn 1
**User**
> How does a predictive cancer biomarker differ from a prognostic biomarker?
**Med Advisor**
A **prognostic biomarker** estimates the likelihood of a clinical outcome—such as recurrence, survival, or progression—**regardless of the treatment** a patient receives. It helps predict who might do better or worse based on their biology. Examples include ER/PR/HER2 status in breast cancer, which can inform prognosis and treatment options, and certain genetic alterations that correlate with overall survival.
A **predictive biomarker** estimates whether a specific treatment is likely to produce a benefit—**compared with another treatment or with no treatment**. It helps select the therapy that is expected to work best for that patient. Examples include EGFR mutations predicting response to EGFR-targeted therapy, PD-L1 expression predicting benefit from immunotherapy, and BRCA mutations predicting benefit from PARP inhibitors.
Key distinction:
- **Prognostic:** “What is likely to happen?”
- **Predictive:** “Which treatment is likely to help?”
A biomarker can sometimes serve both roles—for example, HER2 amplification is prognostic in some contexts and predictive of benefit from HER2-directed therapy. But a biomarker is not automatically predictive; it must be validated in a specific treatment context.
In practice, both types are used to guide decisions, but predictive biomarkers are generally more directly tied to treatment selection, while prognostic biomarkers mainly inform prognosis and risk stratification.
### Turn 2
**User**
> Got it—so the operative distinction is the treatment-by-biomarker interaction, right? Just to make it explicit: a purely prognostic marker shifts outcome the same way across arms, whereas a predictive one needs a differential treatment effect to hold up in validation. Is that the standard framing?
**Med Advisor**
Yes—that’s the standard framing.
A **prognostic** biomarker is associated with the outcome **regardless of treatment**. It shifts risk or prognosis the same way across treatment arms. In a trial, it may help stratify patients or estimate baseline risk.
A **predictive** biomarker is associated with a **differential treatment effect**—that is, the benefit of one treatment over another differs by biomarker status. The treatment-by-biomarker interaction is the operative distinction: prognostic markers don’t change how much a treatment helps; predictive markers do.
Two refinements:
- “Purely prognostic” is a useful ideal, but a biomarker can also be predictive and prognostic. HER2 status is a classic example.
- A statistical interaction is not automatically clinically meaningful; validation requires showing the differential benefit holds up in a defined treatment context.
So: prognostic = same outcome shift across arms; predictive = different treatment effect across arms.
---
[← T09](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t09-testicular-torsion-note.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md)
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*

13
generation_config.json Normal file
View File

@@ -0,0 +1,13 @@
{
"bos_token_id": 151643,
"do_sample": true,
"eos_token_id": [
151645,
151643
],
"pad_token_id": 151643,
"temperature": 0.6,
"top_k": 20,
"top_p": 0.95,
"transformers_version": "4.57.1"
}

151388
merges.txt Normal file
View File

File diff suppressed because it is too large Load Diff

3
model-00001-of-00002.safetensors Normal file
View File

@@ -0,0 +1,3 @@
version https://git-lfs.github.com/spec/v1
oid sha256:84645133ed2de0953205ba52635f61a61717dd8e288a415b897630af92f73dae
size 4967215360

3
model-00002-of-00002.safetensors Normal file
View File

@@ -0,0 +1,3 @@
version https://git-lfs.github.com/spec/v1
oid sha256:472686f9f6187d686301627b36838ae575e42d97ae99331201dca03ff5ba977f
size 3855679144

407
model.safetensors.index.json Normal file
View File

@@ -0,0 +1,407 @@
{
"metadata": {
"total_parameters": 4022468096,
"total_size": 8822848512
},
"weight_map": {
"lm_head.weight": "model-00002-of-00002.safetensors",
"model.embed_tokens.weight": "model-00001-of-00002.safetensors",
"model.layers.0.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.0.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.0.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.0.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.0.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.0.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.0.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.0.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.0.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.0.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.0.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.1.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.1.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.1.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.1.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.1.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.1.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.1.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.1.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.1.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.1.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.1.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.10.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.10.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.10.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.10.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.10.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.10.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.10.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.10.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.10.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.10.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.10.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.11.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.11.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.11.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.11.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.11.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.11.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.11.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.11.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.11.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.11.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.11.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.12.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.12.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.12.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.12.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.12.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.12.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.12.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.12.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.12.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.12.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.12.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.13.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.13.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.13.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.13.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.13.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.13.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.13.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.13.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.13.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.13.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.13.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.14.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.14.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.14.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.14.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.14.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.14.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.14.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.14.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.14.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.14.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.14.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.15.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.15.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.15.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.15.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.15.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.15.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.15.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.15.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.15.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.15.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.15.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.16.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.16.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.16.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.16.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.16.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.16.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.16.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.16.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.16.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.16.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.16.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.17.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.17.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.17.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.17.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.17.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.17.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.17.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.17.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.17.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.17.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.17.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.18.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.18.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.18.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.18.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.18.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.18.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.18.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.18.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.18.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.18.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.18.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.19.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.19.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.19.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.19.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.19.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.19.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.19.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.19.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.19.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.19.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.19.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.2.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.2.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.2.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.2.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.2.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.2.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.2.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.2.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.2.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.2.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.2.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.20.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.20.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.20.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.20.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.20.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.20.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.20.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.20.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.20.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.20.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.20.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.21.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.21.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.21.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.21.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.21.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.21.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.21.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.21.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.21.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.21.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.21.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.22.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.22.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.22.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.22.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.22.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.22.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.22.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.22.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.22.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.22.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.22.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.23.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.23.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.23.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.23.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.23.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.23.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.23.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.23.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.23.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.23.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.23.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.24.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.24.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.24.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.24.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.24.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.24.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.24.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.24.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.24.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.24.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.24.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.25.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.25.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.25.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.25.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.25.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.25.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.25.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.25.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.25.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.25.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.25.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.26.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.26.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.26.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.26.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.26.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.26.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.26.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.26.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.26.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.26.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.26.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.27.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.27.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.27.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.27.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.27.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.27.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.27.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.27.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.27.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.27.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.27.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.28.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.28.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.28.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.28.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.28.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.28.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.28.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.28.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.28.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.28.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.28.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.29.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.29.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.29.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.29.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.29.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.29.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.29.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.29.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.29.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.29.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.29.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.3.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.3.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.3.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.3.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.3.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.3.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.3.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.3.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.3.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.3.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.3.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.30.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.30.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.30.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.30.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.30.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.30.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.30.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.30.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.30.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.30.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.30.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.31.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.31.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.31.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.31.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.31.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.31.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.31.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.31.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.31.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.31.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.31.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.32.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.32.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.32.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.32.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.32.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.32.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.32.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.32.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.32.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.32.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.32.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.33.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.33.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.33.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.33.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.33.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.33.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.33.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.33.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.33.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.33.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.33.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.34.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.34.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.34.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.34.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.34.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.34.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.34.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.34.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.34.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.34.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.34.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.35.input_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.35.mlp.down_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.35.mlp.gate_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.35.mlp.up_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.35.post_attention_layernorm.weight": "model-00002-of-00002.safetensors",
"model.layers.35.self_attn.k_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.35.self_attn.k_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.35.self_attn.o_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.35.self_attn.q_norm.weight": "model-00002-of-00002.safetensors",
"model.layers.35.self_attn.q_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.35.self_attn.v_proj.weight": "model-00002-of-00002.safetensors",
"model.layers.4.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.4.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.4.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.4.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.4.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.4.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.4.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.4.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.4.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.4.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.4.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.5.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.5.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.5.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.5.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.5.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.5.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.5.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.5.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.5.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.5.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.5.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.6.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.6.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.6.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.6.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.6.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.6.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.6.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.6.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.6.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.6.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.6.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.7.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.7.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.7.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.7.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.7.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.7.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.7.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.7.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.7.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.7.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.7.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.8.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.8.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.8.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.8.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.8.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.8.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.8.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.8.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.8.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.8.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.8.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.9.input_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.9.mlp.down_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.9.mlp.gate_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.9.mlp.up_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.9.post_attention_layernorm.weight": "model-00001-of-00002.safetensors",
"model.layers.9.self_attn.k_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.9.self_attn.k_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.9.self_attn.o_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.9.self_attn.q_norm.weight": "model-00001-of-00002.safetensors",
"model.layers.9.self_attn.q_proj.weight": "model-00001-of-00002.safetensors",
"model.layers.9.self_attn.v_proj.weight": "model-00001-of-00002.safetensors",
"model.norm.weight": "model-00002-of-00002.safetensors"
}
}

31
special_tokens_map.json Normal file
View File

@@ -0,0 +1,31 @@
{
"additional_special_tokens": [
"<|im_start|>",
"<|im_end|>",
"<|object_ref_start|>",
"<|object_ref_end|>",
"<|box_start|>",
"<|box_end|>",
"<|quad_start|>",
"<|quad_end|>",
"<|vision_start|>",
"<|vision_end|>",
"<|vision_pad|>",
"<|image_pad|>",
"<|video_pad|>"
],
"eos_token": {
"content": "<|im_end|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false
},
"pad_token": {
"content": "<|endoftext|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false
}
}

BIN
tokenizer.json (Stored with Git LFS) Normal file
View File

Binary file not shown.

239
tokenizer_config.json Normal file
View File

@@ -0,0 +1,239 @@
{
"add_bos_token": false,
"add_prefix_space": false,
"added_tokens_decoder": {
"151643": {
"content": "<|endoftext|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151644": {
"content": "<|im_start|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151645": {
"content": "<|im_end|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151646": {
"content": "<|object_ref_start|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151647": {
"content": "<|object_ref_end|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151648": {
"content": "<|box_start|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151649": {
"content": "<|box_end|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151650": {
"content": "<|quad_start|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151651": {
"content": "<|quad_end|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151652": {
"content": "<|vision_start|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151653": {
"content": "<|vision_end|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151654": {
"content": "<|vision_pad|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151655": {
"content": "<|image_pad|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151656": {
"content": "<|video_pad|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": true
},
"151657": {
"content": "<tool_call>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151658": {
"content": "</tool_call>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151659": {
"content": "<|fim_prefix|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151660": {
"content": "<|fim_middle|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151661": {
"content": "<|fim_suffix|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151662": {
"content": "<|fim_pad|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151663": {
"content": "<|repo_name|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151664": {
"content": "<|file_sep|>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151665": {
"content": "<tool_response>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151666": {
"content": "</tool_response>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151667": {
"content": "<think>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
},
"151668": {
"content": "</think>",
"lstrip": false,
"normalized": false,
"rstrip": false,
"single_word": false,
"special": false
}
},
"additional_special_tokens": [
"<|im_start|>",
"<|im_end|>",
"<|object_ref_start|>",
"<|object_ref_end|>",
"<|box_start|>",
"<|box_end|>",
"<|quad_start|>",
"<|quad_end|>",
"<|vision_start|>",
"<|vision_end|>",
"<|vision_pad|>",
"<|image_pad|>",
"<|video_pad|>"
],
"bos_token": null,
"clean_up_tokenization_spaces": false,
"eos_token": "<|im_end|>",
"errors": "replace",
"extra_special_tokens": {},
"model_max_length": 131072,
"pad_token": "<|endoftext|>",
"split_special_tokens": false,
"tokenizer_class": "Qwen2Tokenizer",
"unk_token": null
}

1
vocab.json Normal file
View File

File diff suppressed because one or more lines are too long